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 We have recently identified a CD11b+Gr1intF4/80+ (Gr1int) regulatory, non-migratory, cell type 
in the lung that is able to suppress a Th2 effector response via secretion of Interleukin-10 (IL-
10), arginase 1 (Arg1) and nitric oxide (NO).  These regulatory lung Gr1int cells also secrete 
Interleukin-6 (IL-6) and Granulocyte macrophage-colony stimulating factor (GM-CSF), but low 
levels of Interleukin-12 (IL-12).  Our studies show that although Gr1int cells are present in the 
lung of naïve mice, their frequency increases in the interstitium following 
endotoxin/lipopolysaccharide (LPS) exposure in a TLR4/MyD88-dependent fashion.  The 
suppressive function of these Gr1int cells is significant in the context of allergic inflammation, 
and because this suppressive cell type accumulates in the lung in response to a bacterial cell wall 
component, they may be a mechanism underlying the hygiene hypothesis, which was postulated 
in 1989 to describe the observation that despite increased sanitation in westernized countries, the 
prevalence of allergies is steadily increasing.  Because of the potent suppressive capacity of lung 
Gr1int, they are now recognized as lung myeloid derived suppressor cells (lung-MDSCs)1.  We 
sought to gain a better understanding of their development to allow for improved therapeutic 
targets during allergic inflammation. 
Secondly, the rapid appearance of these cells in response to a TLR ligand, combined with 
their non-migratory nature and their anatomical location in the lung interstitium, suggests a 
unique function during host defense against bacterial infections.  Much is already known about 
the role of alveolar macrophages and neutrophils in host defense against Klebsiella pneumoniae, 
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but little is known about host defense mechanisms in the lung tissue/interstitium.  Therefore, we 
have also examined the role of MDSC-like cells in defense against K. pneumoniae.   
Briefly, although an inflammatory response in the lung is required to fight the causative 
agent, persistent tissue-resident neutrophils can induce collateral tissue damage and precipitate 
acute lung injury during non-resolving pneumonia.  Little is known about mechanisms 
orchestrated in the lung tissue that remove apoptotic neutrophils to restore tissue homeostasis.  
We show that these MDSC-like cells increase following exposure to K. pneumoniae, are able to 
efferocytose apoptotic neutrophils and are a major source of IL-10 in the lung late after infection.  
Furthermore, using IL-10-/- mice, we show that IL-10 is critical for the control of neutrophilia 
and restoration of homeostasis.  Finally, because IFNγ-STAT1 signaling is known to inhibit IL-
10, we examined the lungs of STAT1-/- mice.  The lung neutrophil burden was attenuated in 
infected STAT1-/- mice with concomitant increase in the frequency of the MDSC-like cells and 
lung IL-10 levels. Thus, inhibiting STAT1 in combination with antibiotics may be a novel 
therapeutic strategy to address inefficient resolution of bacterial pneumonia.  The inhibition of 
STAT1 may also be relevant in the context of allergic inflammation when a greater 
immunosuppressive force, or increased numbers of lung MDSCs, would be advantageous to 
temper lung inflammation. 
 
 
 vi 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS .................................................................................................... XIV	  
LIST OF ABBREVIATIONS ................................................................................................. XVI	  
1.0	   INTRODUCTION ............................................................................................................... 1	  
1.1	   THE IDENTIFICATION OF A LUNG-MDSC LIKE CELL ................................ 1	  
1.1.1	   The relationship between endotoxin exposure and immunosuppression; 
the hygiene hypothesis ................................................................................................. 3	  
1.1.2	   MDSCs and allergic inflammation ................................................................. 5	  
1.1.3	   Lung MDSC suppression of Th2 immunity ................................................... 6	  
1.2	   REGULATION OF MDSC ACCUMULATION AND FUNCTION ..................... 7	  
1.2.1	   Development of murine myeloid cell lineages. ............................................... 9	  
1.2.2	   TLR signaling and regulation of inflammation ........................................... 10	  
1.2.3	   GM-CSF and its role in augmenting LPS-TLR4 signaling ........................ 12	  
1.2.4	   IL-6 and STAT3 signaling in MDSC differentiation, function, and lung 
homeostasis. ................................................................................................................ 14	  
1.2.5	   STAT1/STAT3 Crosstalk .............................................................................. 15	  
1.3	   THE COORDINATION OF EARLY AND LATE PULMONARY HOST 
DEFENSE ............................................................................................................................ 16	  
1.3.1	   The four phases of host defense .................................................................... 17	  
 vii 
1.3.2	   Innate Host Defense Against Klebsiella pneumoniae .................................. 18	  
1.3.3	   Alveolar Macrophages vs Tissue Macrophage Subsets .............................. 20	  
1.3.4	   STAT1 in host defense ................................................................................... 21	  
1.3.5	   Neutrophils ..................................................................................................... 22	  
1.3.6	   Neutrophil Recruitment in Response to K. pneumoniae. ............................ 23	  
1.3.7	   Neutrophil Apoptosis and Clearance (Efferocytosis) ................................. 24	  
1.4	   INTERLEUKIN-10 ................................................................................................... 27	  
1.4.1	   Early vs. Late IL-10 production in host defense ......................................... 27	  
1.4.2	   IL-10 production by myeloid cells ................................................................ 28	  
1.4.3	   IL-10 contributes to Neutrophil Clearance and Resolution of 
Inflammation .............................................................................................................. 30	  
2.0	   THE DEVELOPMENT OF A LUNG MDSC-LIKE CELL .......................................... 32	  
2.1	   ABSTRACT ............................................................................................................... 32	  
2.2	   INTRODUCTION ..................................................................................................... 33	  
2.3	   MATERIALS AND METHODS .............................................................................. 36	  
2.3.1	   Animals and reagents ..................................................................................... 36	  
2.3.2	   Induction of allergic airway inflammation by HDM .................................. 37	  
2.3.3	   Generation of LPS-induced cells in vivo ...................................................... 37	  
2.3.4	   Generation of DCs and CD11b+Gr1+ cells from bone marrow cells in 
vitro…. ......................................................................................................................... 38	  
2.3.5	   Phenotypic evaluation of CD11b+Gr1int cells and cDCs ............................. 39	  
2.3.6	   Colorimetric assay for Nitric Oxide (NO) .................................................... 39	  
2.3.7	   Neutralization of GM-CSF in vivo ................................................................ 40	  
 viii 
2.3.8	   Statistical analyses .......................................................................................... 40	  
2.4	   RESULTS ................................................................................................................... 40	  
2.4.1	   Lung MDSC-like cells expand in response to LPS in contrast to lung 
DC…… ........................................................................................................................ 40	  
2.4.2	   Lung MDSC produce IL-10 and NO in a dose dependent manner. .......... 44	  
2.4.3	   High dose LPS is required to suppress HDM-driven eosinophilia. ........... 46	  
2.4.4	   Lung MDSC-like cells can be generated from lineage negative progenitors 
in vitro. ......................................................................................................................... 47	  
2.4.5	   Neutralization of GM-CSF alters lung-MDSC cytokine profile. ............... 50	  
2.4.6	   Generation of MDSC is reduced in the absence of STAT5A signaling in 
vitro and in vivo. .......................................................................................................... 53	  
2.4.7	   IL-6 is an MDSC-survival factor ex vivo. ..................................................... 57	  
2.4.8	   Interleukin-6 is critical for survival following intratracheal LPS 
administration. ........................................................................................................... 57	  
2.4.9	   STAT1 is a negative regulator of MDSC-like cell accumulation in the 
lung…. ......................................................................................................................... 58	  
2.5	   DISCUSSION ............................................................................................................. 59	  
3.0	   A ROLE FOR IL-10 IN EFFEROCYTOSIS OF APOPTOTIC NEUTROPHILS AND 
RESOLUTION OF INFLAMMATION PRODUCED BY STAT1-REGULATED LUNG 
MDSC-LIKE CELLS ................................................................................................................. 62	  
3.1	   ABSTRACT ............................................................................................................... 62	  
3.2	   INTRODUCTION ..................................................................................................... 63	  
3.3	   MATERIALS AND METHODS .............................................................................. 66	  
 ix 
3.3.1	   Animals and reagents ..................................................................................... 66	  
3.3.2	   Infection .......................................................................................................... 66	  
3.3.3	   Generation and isolation of MDSC-like Gr1int cells from the lung ........... 67	  
3.3.4	   Histology and quantitation using Metamorph ............................................ 67	  
3.3.5	   Efferocytosis assay ......................................................................................... 68	  
3.3.6	   Intracellular cytokine staining ...................................................................... 68	  
3.3.7	   pSTAT3 analysis ............................................................................................ 69	  
3.3.8	   qRT-PCR ........................................................................................................ 69	  
3.3.9	   Cytokine analysis by ELISA ......................................................................... 70	  
3.3.10	   Statistical analyses ........................................................................................ 70	  
3.4	   RESULTS ................................................................................................................... 71	  
3.4.1	   Establishment of an LD50 dose of K. pneumoniae ....................................... 71	  
3.4.2	   Early Versus Late Interleukin-10 during infection By Klebsiella 
pneumoniae ................................................................................................................. 74	  
3.4.3	   Gr1int MDSC-like cells expand in response to K. pneumoniae and produce 
IL-10… ........................................................................................................................ 79	  
3.4.4	   Gr1int MDSC-like cells are outnumbered by neutrophils at high bacterial 
dose…. ......................................................................................................................... 82	  
3.4.5	   Lung MDSC-like cells have the ability to efferocytose apoptotic 
neutrophils. ................................................................................................................. 84	  
3.4.6	   Regulation of Gr1int:PMN ratio by STAT1 ................................................. 86	  
3.5	   DISCUSSION ............................................................................................................. 91	  
3.6	   ACKNOWLEDGEMENTS ...................................................................................... 96	  
 x 
4.0	   CONCLUSIONS ................................................................................................................ 97	  
5.0	   FUTURE DIRECTIONS ................................................................................................. 100	  
6.0	   PUBLICATIONS ............................................................................................................. 104	  
APPENDIX A ............................................................................................................................ 105	  
BIBLIOGRAPHY ..................................................................................................................... 106	  
 xi 
LIST OF FIGURES 
 
Figure 1. Schematic depicting regulation of lung-MDSC accumulation and function. ................ 33	  
Figure 2: Generation of lung MDSC requires GM-CSF and LPS, signaling via STAT5 for the 
production of IL-6. ........................................................................................................................ 35	  
Figure 3. MDSC-like cells (Gr1int) expand in response to LPS. ................................................... 42	  
Figure 4. Lung dendritic cells are identified by low autofluorescence and MHCII expression, and 
their numbers decrease in the lung after LPS administration. ...................................................... 43	  
Figure 5. Ratio of MDSC:DC increases over time in the lung post LPS-treatment. .................... 44	  
Figure 6. MDSC-like cells (Gr1int) expand in response to LPS and produce IL-10 and Nitric 
Oxide. ............................................................................................................................................ 45	  
Figure 7. Suppression of house dust mite (HDM)-driven eosinophilic inflammation in the 
airways by LPS. ............................................................................................................................ 47	  
Figure 8. MDSC-like cells can be generated in vitro under conditions of GM-CSF and LPS. .... 48	  
Figure 9. A triple positive (CD11b+Gr1intF4/80+) cell population is found with increased 
frequency in GM-CSF + LPS culture conditions. ......................................................................... 49	  
Figure 10. MDSC like cells can be generated from lineage negative progenitors in vitro. .......... 50	  
Figure 11. LPS alone does not generate a Thy1.2+ bone marrow MDSC-like cell. ..................... 51	  
 xii 
Figure 12. Neutralization of GM-CSF during LPS administration alters cytokine profile of lung 
MDSC-like cells. ........................................................................................................................... 52	  
Figure 13. Reduced F4/80+Gr1int expression in the presence of neutralizing GM-CSF antibody. 53	  
Figure 14. STAT5A deficiency alters BMDC and MDSC generation in vitro with reduced IL-6 
production. .................................................................................................................................... 55	  
Figure 15. Gr1int accumulation is reduced in STAT5A-/- mice, and Gr1int cells produce less IL-6 
as compared to WT MDSC-like cells in the lung. ........................................................................ 56	  
Figure 16. Gr1int cells produce IL-6 and neutralization of IL-6 reduces the number of Gr1int cells 
cultured ex vivo. ............................................................................................................................ 57	  
Figure 17. IL-6 is critical for survival following intratracheal LPS administration. .................... 58	  
Figure 18. Establishment of an LD50 dose of K. pneumoniae infection ....................................... 72	  
Figure 19. Survivors display better parameters of health compared to moribund mice, both 
infected with 1000 CFU of bacteria. ............................................................................................. 73	  
Figure 20. IL-10 deficiency worsens outcome late after infection. .............................................. 75	  
Figure 21. Improved bacterial clearance and increased PMN recruitment in IL-10-/- mice. ........ 77	  
Figure 22. Increased expression of cytokines and chemokines associated with neutrophil 
recruitment in IL-10-/- mice. .......................................................................................................... 78	  
Figure 23. Gr1int MDSC-like cells are the IL-10 producers in the lung interstitium 72 h post 
infection. ....................................................................................................................................... 81	  
Figure 24. AMs decrease over time post infection. ...................................................................... 82	  
Figure 25. Increased PMN infiltration in the lung at higher bacterial burden resulting in an 
increased PMN:Gr1int ratio. .......................................................................................................... 83	  
Figure 26. Gr1int cells efferocytose apoptotic PMNs. ................................................................... 85	  
 xiii 
Figure 27. STAT1-/- mice show reduced cellular infiltration upon gross examination with 
decreased frequency of PMNs and increased frequency of Gr1int cells in the lungs following 
1000 CFU K. pneunoniae infection. ............................................................................................. 88	  
Figure 28. STAT1-/- mice show increased systemic CFU 72 hours post infection. ...................... 89	  
Figure 29. STAT1-/- have increased Gr1int following infection with 1000 CFU K. pneumoniae or 
LPS administration........................................................................................................................ 90	  
Figure 30. STAT1-/- Gr1int have increased pSTAT3 in response to IL-6 treatment. ................... 91	  
Figure 31. Gr1int cells can phagocytose Gram-negative bacteria in vitro and in vivo. ............... 102	  
 
 
 xiv 
ACKNOWLEDGEMENTS 
During the last 6 years, I often thought to myself “If only getting my PhD was a team thing 
instead of something I have to do on my own.”  Although much of the thesis is a solo task, it 
would show lack of integrity on my part if I thought that getting my PhD was an independent 
process.  I’d like to thank Drs. Adriana Larregina, Angus Thomson, Paul Monga, and Yatin Vyas 
for serving on my thesis committee, specifically for their time, direction, and support.  You have 
all been an inspiration.  I’d also like to thank Sharon Washington, Cindy Duffy, and Anna Marie 
for handling the details that made it possible for me to be a student at Pitt.  Anna Marie – I just 
might owe you 12 pounds of chocolate. 
To all the members of the Ray laboratory, both past and present, I am truly thankful to 
have been a part of you.  You provided time, ideas, and support in so many ways.  During my 
third year I found truth in a fortune cookie, which stated: “Always surround yourself with true 
friends.”  I have indeed been blessed.  Nandini – you’ve been a model of integrity and humility 
to me in more ways than you will ever know.  I’ll never forget the ways you found to care for me 
even in my darkest moments.  Nina – thank God for a co-worker to “run it out” with.  Those 
conversations over lunch and on the trails set me in motion to finish strong.  I appreciate your 
friendship so much.  Anupriya – thank you for all the adventures, advice, and for always 
somehow having age-matched WT mice for me.  I don’t know how you do it!  Tim – thank you 
for the tremendous amount of editing, direction, encouragement, and for always keeping life in 
 xv 
perspective.  Thank you also for letting me borrow your ice-bucket, multiple times, without you 
knowing.  Zengbiao, Meenakshi, Rachael, Mahesh, Mingjian, Shikha, and Manohar – thank you 
for your scientific advice and support, the willing hands to help, and the laughs in the lunchroom.  
It’s the little things that make up the every day and I won’t ever forget you guys! 
To my mentors, Anuradha, and Prabir Ray.  Thank you for your time, energy, and 
commitment to my success.  Your passion for science is infectious and if I can carry even a bit of 
it with me forward, I will be grateful.  I am also so thankful for the patience that you 
demonstrated towards me as I progressed as a graduate student.  
I want to thank my parents, Richard and Christine, my family, and my close friends - you 
know who you are.  Thank you for your prayers and encouragement throughout my whole life, 
especially the last 6 years as they have been incredibly challenging.  Thank you for your 
consistent persuasion that I need to be faithful to the task set before me.  You are all wonderful.  
Jerrod, you are my favorite and very best friend.  You help me keep life in perspective and have 
the uncanny ability to make me laugh out loud when I think the world is ending around me.  I 
don’t know what I did before you. 
To all of you, I pray that health and true joy may be yours always.   
 
 
 
 
 
 
 
 xvi 
LIST OF ABBREVIATIONS 
A 
AF: autofluorescence  
AHR: airway hyperresponsiveness 
AMs: alveolar macrophages 
B 
BALF: bronchoalveolar lavage fluid  
BM: bone marrow 
BMDC: bone marrow-derived dendritic cell 
C 
C/EBP: CCAAT Enhancer Binding Protein 
CLP: common lymphoid precursor 
CMP: common myeloid precursor 
CTL: cytotoxic T lymphocyte 
D 
d: day(s) 
DC: dendritic cells 
dLN: draining lymph node 
DSS: dextran sulfate sodium 
E 
E. coli: Escherichia coli 
Eos: eosinophils 
F 
FSC: forward scatter 
G 
 xvii 
GM-CSF: Granulocyte-macrophage colony-stimulating-factor 
GMP: granulocyte macrophage progenitor 
GPI: glycoslphosphatidylinositol 
GSK3: glycogen synthase kinase 3 
H 
HDM: house dust mite 
h: hour(s) 
HSC: hematopoietic stem cell 
HSPC: hematopoietic stem and progenitor cell 
Hsp: heat shock protein 
I 
IL: interleukin 
IM: interstitial macrophage 
iNOS: inducible nitric oxide synthase 
i.t.: intratracheally 
IRAK: interleukin-1 receptor-associated kinase 
ITAM: intracellular tyrosine kinase activation motif  
J 
JAK: Janus kinase 
K 
KC/CXCL1: Chemokine (C-X-C motif) ligand 1 
KO: knockout (mice) 
L 
L-NAME: L-NG-Nitroarginine methyl ester 
LPS: lipopolysaccharide 
M 
MAP: Mitogen-activated protein 
MDP: macrophage/dendritic cell progenitors  
MDSC: myeloid-derived suppressor cell 
MFI: mean fluorescence intensity 
MIP: macrophage inflammatory protein 
 xviii 
miR: microRNA 
MPO: myeloperoxidase 
N 
NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells 
Neu: neutrophils 
P 
PAMP: pathogen-associated molecular pattern 
pDC: plasmacytoid DC 
PI3K: Phosphoinositide 3-kinase 
PMN: polymorphonuclear  
PRR: pattern recognition receptor 
PTX3: pentraxin 3 
Q 
qRT-PCR: quantitative reverse-transcription PCR  
R 
RANTES/CCL5: Regulated upon Activation, Normal T Cell Expressed, and Secreted 
S 
SCF: stem cell factor 
SSC: side scatter 
STAT: signal transducers and activators of transcription 
T 
TIRAP: toll-interleukin 1 receptor (TIR) domain containing adaptor protein 
TRAM: TRIF related adaptor molecule 
TRIF: TIR-domain-containing adaptor-inducing interferon-β 
TRAF6: TNF receptor associated factor 6 
TAK1: transforming growth factor β-activated kinase 1 
TCR: T cell receptor 
Tg: transgenic 
TLR: toll-like receptor 
V 
VEGF: vascular endothelial growth factor 
 xix 
W 
WT: wild type  
 
 1 
1.0  INTRODUCTION 
1.1 THE IDENTIFICATION OF A LUNG-MDSC LIKE CELL 
The orchestration of an appropriate immune response is dependent upon the ability of the 
immune system to discriminate between self and non-self and, the timely resolution of 
inflammation to prevent tissue injury.  Both inappropriate and appropriate immune responses 
must be counteracted by regulatory mechanisms to maintain body-wide homeostasis.  Over the 
years many investigators have questioned the nature of these interactions, experimentally 
detailing the derivation of inflammatory vs. regulatory responses, cellular differentiation, and the 
importance of cytokines and intracellular signaling molecules for the determination of immune 
outcomes.  Much of this work is organ specific and it has become increasingly clear that it is not 
only the particular cell types involved, but the nature of the infection and extracellular milieu that 
contributes to their function2, the culmination of which defines the result. 
The so-called “hygiene hypothesis” was proposed to explain the ongoing increase in 
allergy and autoimmunity in westernized cultures.  Essentially, it postulates that early exposure 
of the immune system to otherwise innocuous antigens is necessary to induce immunological 
tolerance, and thus prevent aberrant immune responses leading towards allergic and autoimmune 
conditions later in life.  Studies, initiated in our laboratory in 2007 (described in detail in Section 
1.1.3), introduced a connection between environmental exposure to endotoxin and the 
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establishment of immunological tolerance, thereby providing a potential mechanism underlying 
the hygiene hypothesis.  Briefly, in response to intratracheal administration of LPS, an 
interleukin-10 (IL-10) producing myeloid-lineage cell population expanded in the lung tissue, 
which was phenotypically similar to the myeloid-derived suppressor cells (MDSCs) commonly 
associated with anti-tumor immunity3.  These regulatory cells expressed CD11b, intermediate 
levels of Gr1, and F4/80, and were expanded in a TLR4/MyD88-dependent manner.  As such, 
they were phenotypically and morphologically similar to cells described as being present in 
tumor microenvironments4.  The MDSC-like cells we described expanded in the lung tissue in a 
dose dependent manner in response to intratracheal administration of bacterial 
lipopolysaccharide (LPS).  In contrast to lung DC, these MDSC-like cells did not traffic to the 
lung draining lymph nodes, allowing them to act in a dominant fashion suppressing DC-mediated 
regulation of Th2 responses in situ.  The MDSC-like cells were found to blunt the ability of the 
lung DCs to induce GATA-3 upregulation or STAT5 activation in primed Th2 cells, both 
transcription factors having critical roles in Th2 effector function.  The findings, published in 
Mucosal Immunology in 2010, characterized these cells for the first time as lung MDSCs, with 
the ability to suppress HDM-driven eosinophilic inflammation via IL-10, nitric oxide (NO), and 
arginase-1 (Arg1) expression5. Overall, these studies identified a cellular mechanism that may 
underlie the hygiene hypothesis, thus providing the field with a tangible explanation for why the 
use of antibiotics and improved sanitation in the Western world correlates with an increase in 
atopic disease.  Essentially, decreased exposure to bacterial products including LPS particularly 
early in life may reduce MDSC number and function thereby leading to crippling of 
immunological tolerance and potentially deleterious immune responses. 
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Although this work identified a lung MDSC, greatly advanced the field of lung biology, 
and expanded our understanding of cellular-mediated immunosuppression, we had not yet 
addressed the origin of these lung MDSCs, or the mechanism(s) that controlled their expansion 
in the lung tissue.  Further elucidation of these processes holds the potential for therapeutic 
development of biologically-based approaches to re-establish immunological tolerance in allergy 
and autoimmunity.   
This thesis work is two-fold.  It first focuses on the LPS/TLR4-mediated generation of 
lung MDSCs, and identifies a novel mechanism by which their expansion is regulated.  
Secondly, given the expansion of this cell type in response to a bacterial component, it 
characterizes the importance of lung MDSCs and their IL-10 production in the control of 
neutrophils following bacterial pneumonia.  Taken together, the data generated herein contribute 
to our current understanding of MDSC biology and make advances towards harnessing them for 
therapeutic intervention. 
1.1.1 The relationship between endotoxin exposure and immunosuppression; the hygiene 
hypothesis 
The chronic inflammatory state found in asthmatics is maintained due to repeated interactions 
between an allergen(s) and the immune system of susceptible individuals.  Once initiated, 
disease is perpetuated upon epithelial cell involvement and leukocyte influx, with chronic 
inflammation finally resulting in excessive collagen deposition and the development of fibrosis 
in the lung tissue.  To explain the recent increase in the prevalence of atopic diseases in 
developed countries, the hygiene hypothesis was postulated in 1989, contending that due to 
improved sanitation and cleaner lifestyles, microbial exposures in childhood are reduced6.  
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Several investigators reported findings supporting this concept, most notably, von Mutius and 
colleagues, who documented an inverse correlation between endotoxin levels measured in 
children’s mattresses and the development of hay fever and atopic asthma7.  Additionally, 
allergic disease was lower in children who were enrolled in day care at an early age, which 
presumably was mediated by community-associated exposure to a wide range of environmental 
antigens8.    
From an immunological perspective, the observed inverse relationship between allergic 
disease, hay fever, and family size was initially attributed to the ability of early pathogenic 
exposures to tip the balance away from the reported default Th2 bias in neonates9.  However, it is 
now accepted that the mechanism cannot simply be Th1/Th2 cross-regulation since parasitic 
exposure resulting in high IL-10 levels also protected from allergic disease10.  Additionally, 
Th1/Th17-driven pathology in autoimmune diseases such as multiple sclerosis and diabetes 
mellitus have also been similarly reported with increased frequency in western societies11.  
Therefore, it appears that the breach of tolerance observed in allergic disease and other disorders 
may be due to a failure in fundamental tolerogenic mechanisms, and that lack of homeostatic 
maintenance leads to aberrant immune responses.  Indeed, the publication from our laboratory 
described above suggests a connection between environmental exposure to endotoxin and the 
promotion of tolerance via the induction of lung-MDSCs, thus representing a mechanism of 
regulation potentially applicable to a wide range of conditions characterized by heightened 
immune activation5.   
Although bacterial lipopolysaccharide (LPS) has been described as an adjuvant in the 
development of allergic inflammation, it also can have differential effects depending on the dose 
used.  A low dose (<1 ng) has been shown to promote Th2 eosinophilic inflammation while a 
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higher dose (~100 ng) was shown to favor neutrophilia suggestive of a Th1 or Th17 response12. 
Higher doses (in the µg range) actually inhibit airway inflammation12,13.  The increased 
neutrophilia in response to an intermediate dose of LPS is interesting given that the traditional 
method of quantifying neutrophilia is based upon morphology and phenotypic markers.  It is 
plausible that, although neutrophilia is indeed a response to high-dose LPS, a subset of those 
“neutrophils” were actually MDSC-like cells, similar on the basis of CD11b and Gr1 expression, 
two phenotypic markers that are shared between these myeloid subsets, but that are functionally 
distinct.  
A mechanism underlying this low to high dose-response continuum of LPS in the 
promotion of allergic immunological responses was uncovered in 2009 with the discovery that 
Der p 2, the main allergen in house-dust mite (HDM) has structural homology with MD-2, the 
LPS binding component of the TLR4 signaling complex14.  Airway epithelial cells do not 
express MD-2, but are known to express TLR415.  HDM-Der p 2, functioning as a molecular 
mimic of MD-2, may explain why a very low dose of LPS in the presence of HDM, can enhance 
a Th2 response in the lung.  Furthermore, the presence of TLR4 on epithelial cells is critical for 
the initiation of HDM-driven allergic airway inflammation16.  The development of 
immunosuppressive MDSC-like cells in response to endotoxin suggests a mechanism by which 
nature may limit atopic disease in cases where environmental exposure to LPS is increased or 
even extreme. 
1.1.2 MDSCs and allergic inflammation 
Prior to our publication demonstrating in vivo generation of lung MDSCs following exposure to 
LPS5, little had been established regarding the role of MDSCs in the down-regulation of allergic 
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inflammation.  In fact, the majority of publications involving MDSCs/MDSC-like cells or 
MDSC expansion described a cell type which actually favors a Th2 response17-20.  Discrepancies 
between these studies and ours can likely be explained by differing microenvironments 
contributing to the generation and function of these MDSC like cell subsets in particular 
situations. 
1.1.3 Lung MDSC suppression of Th2 immunity 
MDSCs are historically known to inhibit both T-cell proliferation and Th1-immune responses in 
the context of anti-tumor immunity3,21,22, but in 2010 we demonstrated the ability of lung 
MDSC-like cells to blunt the Th2 effector response in the lung5.  Using both an HDM-driven 
model of allergic inflammation as well as in vitro co-culture of lung MDSCs with primed Th2 
cells, we showed that LPS-generated lung MDSCs could dampen Th2 effector mechanisms.  In 
the presence of lung MDSCs, lung DCs could not promote Th2 cytokine production, upregulate 
GATA-3 expression, or induce STAT5 activation in primed Th2 cells23.  GATA3 and STAT5 are 
critical transcription factors for Th2 effector function, with GATA3 being the factor which drives 
Th2 development, and activated STAT5 being required for the solidification of a potent Th2 cell 
in the lung once it traffics from the lymph node24,25.  Activated STAT5 is required for T1ST2 
expression, a molecule required for Th2 effector function26.  The LPS-mediated lung MDSCs 
produce nitric oxide, Arg1, and IL-10, but also relatively large amounts of IL-6, which was noted 
in culture supernatants.  IL-10 and Arg1 cooperate to suppress GATA3 and nitric oxide was 
responsible for the suppression of pSTAT5.  Nitric oxide is known to block Jak3-mediated 
STAT5 activation27,28. 
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Preliminary studies revealed that one role for MDSC-derived IL-6 production was the 
suppression of DC-induced IFNγ production from T-cells in co-culture.  Previous work from our 
laboratory also recognized IL-6 as a potent inhibitor of Th129.  Importantly, those particular 
experiments were designed as co-cultures of lung DC and MDSC (in varying ratios) together 
with naïve CD4 T-cells.  It was later determined that lung MDSC were not present in lung 
draining lymph nodes (LNs), strongly suggesting that they are primarily tissue resident myeloid 
cells and therefore exert their immunosuppressive force in the periphery.  That being the case, it 
was obvious that co-culture of lung MDSC with naïve T-cells did not accurately recapitulate the 
in vivo cell-cell dynamics.  Therefore, it was deemed necessary to co-culture lung DC and lung 
MDSC with T-cells already primed towards the Th2 lineage, as this would best represent the 
physiological situation found in the lung.  Studies are currently underway to determine the 
influence of MDSCs on Th1 and Th17 effector cell function 
1.2 REGULATION OF MDSC ACCUMULATION AND FUNCTION 
The accumulation of MDSC-type cells in the tumor microenvironment is thought to be 
dependent upon a number of factors such as VEGF, IL-6, GM-CSF, M-CSF, SCF, 
cycloxygenase-2, prostaglandins, TLR ligands and members of the S100 protein family30-35.  
Tumor-generated MDSCs have been characterized with the basic phenotype of CD11b+Gr1+, 
although additional surface molecules such as IL-4Rα, CD115, CD124, PD-L1, and CD80 are 
variable based upon particular microenvironments and tumor types36,37.  Our study demonstrated 
the expansion of CD11b+Gr1intF4/80+ cells in a dose dependent manner following LPS 
administration5. Their expansion was greatly blunted in MyD88-deficient mice suggesting 
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dependence upon this adaptor protein for their accumulation.  It is important to note that a 
number of other studies have also documented the expansion of CD11b+Gr1+ cells in response to 
repeated LPS exposure17,38,39.  CD11b+Gr1+ cells were also identified in the context of microbial 
sepsis and were shown to promote immune suppression via Th2 polarization17.  Although both 
this study and ours demonstrated MyD88 dependence in the accumulation of these myeloid cells, 
their function in terms of Th2 regulation are very different, likely due to differences in 
microenvironment and organ specificity.   
CD11b+Gr1+ MDSC-like cells are present in the bone marrow under homeostatic 
conditions.  Furthermore, suppressive MDSC-like cells have been shown to be generated in 
culture under conditions of low or high concentrations of GM-CSF40.  We demonstrated the in 
vitro generation of CD11b+Gr1int from bone marrow cells under conditions of LPS and GM-
CSF5.  While the presence of GM-CSF alone favors myeloid DC differentiation, the addition of 
LPS blocks DC generation in favor of MDSC-like cells.  In a similar manner, the combination of 
GM-CSF with inflammatory cytokines such as IL-6 or IL-1beta favors the generation of MDSCs 
with T cell suppressive capacity30.  Suppressors of cytokine signaling (SOCS) proteins have 
additionally been shown to play a role in blocking DC differentiation presumably for the purpose 
of favoring macrophage differentiation under conditions where innate host defense is needed for 
protection41.   
Because of the initial association of MDSCs with tumor progression described in the 
literature, a better understanding of their generation and function is necessary for the 
development of novel immunotherapies, not only in the cancer field but also in organ 
transplantation, autoimmune diseases, and allergy42-44.  Importantly, although many investigators 
have sought the mechanisms by which MDSCs are generated via exposure to tumor-secreted 
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factors as well as recruitment into the tumor microenvironment, these processes are still not well 
understood1,21.  
1.2.1 Development of murine myeloid cell lineages.   
The discovery of the hematopoietic stem cell (HSC) provided the basis for the recent exploration 
of lineage differentiation of various types of cells45.  Common-lymphoid, -myeloid, or -
granulocyte progenitors (CLP, CMP, and GMP respectively) can be derived from a single HSC 
from the adult bone marrow.  The process is dependent upon the surrounding growth factors and 
various transcription factors, which allow these progenitors to commit to a particular cell 
lymphoid or myeloid cell type, many of which have been characterized on the basis of surface 
phenotype and function45-47.   
The CMP lineage can give rise to myeloid cells encompassing granulocyte-macrophage, 
macrophage, and granulocyte populations differentiated via GM-CSF, M-CSF, and G-CSF, 
respectively48.  Much of this work has been verified in vitro49.  The addition of GM-CSF to bone 
marrow cells in culture is one method used for the generation of myeloid/conventional dendritic 
cells (cDCs) and M-CSF is added to similar cultures in order to promote bone marrow 
macrophage differentiation. 
PU.1, and C/EBPα/β are two of the critical transcription factors shown to play a role in 
lineage commitment50.  PU.1 plays a fundamental role and is required for HSC to proceed to 
CMP stage, since inhibition of PU.1 results in loss of CMPs, GMPs, and CLPs46.  In contrast, 
CCAAT Enhancer Binding Protein alpha deficient (C/EBPα-/-) mice lack neutrophils and 
eosinophils, and C/EBPβ was recently recognized as a critical transcription factor for neutrophil 
development during stress-induced hematopoiesis51.  C/EBPβ is also critical for bone marrow 
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MDSC generation52.  Furthermore, signal transducers and activators of transcription (STAT) 
molecules as well as interferon regulatory factors (IRFs) are highly involved in regulating 
cellular differentiation53,54.  Myeloid dendritic cell generation requires signaling through STAT5 
downstream of GM-CSF and it was recently shown that plasmacytoid dendritic cell (pDC) 
development involves a blockade of IRF8 by STAT5 during differentiation55.  
1.2.2 TLR signaling and regulation of inflammation 
The toll-like receptors (TLRs) are a family of 13 (in mice) pattern recognition receptors, which 
represent the first line of defense against a variety of microbial pathogens.  Expressed primarily 
on cells involved in innate immunity (epithelial cells, macrophages and dendritic cells (DCs)), 
these TLRs are type 1 membrane proteins with a Toll/interleukin-1 receptor (TIR) domain 
responsible for signal transduction via the TIR domain-containing adaptor molecules including 
MyD88, MyD88-like adaptor (Mal/TIRAP), TRAM, and TRIF.  TLRs form homo or 
heterodimers for pattern recognition and TLR ligation induces DC maturation and triggers 
inflammatory cytokine production (TNFα, IL-6, IL-1β, IFN’s) for host defense56.  TLRs 1, 2, 4 
and 6 are expressed on the cell surface whereas TLRs 3, 7, 8 and 9 are located intracellularly for 
recognition of pathogen-associated nucleic acids.  All TLRs, except for TLR3, associate with 
MyD88 to initiate a common pathway of signal transduction involving activation of IRAK4 and 
IRAK1.  This in turn induces the recruitment and activation of TRAF6, subsequent activation of 
the TAK1 complex, and culminates in IκB phosphorylation and NF-κB activation.  In contrast, 
TLR3 utilizes TRIF and induces activation of interferon regulatory factor 3 (IRF-3), the MAPK-
AP-1 pathway, and/or NF-κB57.  TLR4 is unique given its ability to signal through two adaptor 
proteins, MyD88 and TRIF.  Due to the bipartite nature of TLR4 signaling, there have been 
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many questions regarding how these pathways are controlled.  LPS internalization is independent 
of TLR4 but both LPS and TLR4 are known to traffic between the Golgi apparatus and the 
plasma membrane in a manner independent of signaling58,59.  Furthermore, it has been shown 
that endocytosis of TLR4 is necessary for signaling via the MyD88-independent pathway.  Upon 
TLR4 ligation, MyD88 is recruited to TLR4 at the plasma membrane via TIRAP.  Following 
signaling via MyD88, TRAM is able to bind TLR4 and facilitate interactions between TLR4 and 
TRIF in an endosomal location.  Presumably, in the absence of TLR4 endocytosis, signaling 
through TRIF cannot occur60.  Interestingly, while MyD88 has been linked to an early phase 
activation of NF-κB and MAP kinases upon LPS stimulation, TRIF-dependent signaling has 
been linked to later phase NF-κB and MAP kinase activation61.  Downstream of TLRs, there are 
five NF-κB family members, all having the ability, with the exception of RelB, to form hetero- 
or homodimers for their function, with each member implicated in distinct roles.  
TLR4 signaling has been characterized in a variety of cell types and has a primary 
function of coupling innate and adaptive immunity, but TLR4 has also been shown to promote 
immune homeostasis in the intestine62.  This work, published in 2004, started to uncover the 
delicate balance between TLR stimulation as a way to alert the immune system of foreign 
invaders, while simultaneously maintaining homeostasis in the presence of commensal 
microflora.  Ligation of TLRs is known to provoke an inflammatory response but using a toxic 
model of intestinal inflammation (oral administration of dextran sulfate sodium (DSS), Rakoff-
Nahoum and colleagues demonstrated that TLR ligation was actually required for protection 
from inflammation.  This protective response required MyD88 signaling downstream of TLR 
since MyD88-/- mice exhibited severe mortality following DSS administration.  Although it was 
initially thought that the recognition of commensal bacteria by TLRs would be important to limit 
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infiltrating leukocytes and control bacterial growth; however, it was instead demonstrated that 
TLR ligation was critical for the expression of both heat shock proteins and cytokines, including 
interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α). 
TLRs expressed on precursors of the lymphoid and myeloid derived cell subsets in the 
bone marrow are thought to be important for replenishment of the innate immune system during 
infection.  These progenitors express various TLRs, as well as MD2 and CD14, and have been 
shown to respond to TLR stimulation63.  In 2008 a study showed that migratory hematopoietic 
stem and progenitor cells (HSPCs) traffic continually through extramedullary tissues such as the 
lung and kidneys and can proliferate within these tissues in response to LPS.  TLR4 ligation 
halted the circulation of these progenitor cells via down regulation of sphingosine phosphate 
receptor (SP1), and induced rapid proliferation in situ giving rise to myeloid cells that express 
CD11c and a subset that expressed Gr1 at an intermediate level.  This was one of the first studies 
suggesting the ability of HPCs to differentiate in response to TLR stimulation outside of the 
bone-marrow niche.  The proposed function of these cells was immunosurveillance but the 
authors did not go on to show if or how this cell type contributed to host defense via rapid 
expansion in the tissue64.   To address this issue, we performed experiments utilizing intravenous 
adoptive transfer of a GFP+ lineage negative bone marrow population followed by subsequent 
LPS administration and demonstrated their expansion in the lung parenchyma5.  
1.2.3 GM-CSF and its role in augmenting LPS-TLR4 signaling 
Granulocyte macrophage colony-stimulating factor (GM-CSF) is a growth factor produced by 
many cell types including T cells, macrophages, and tumor cells.  Fibroblasts, endothelial and 
epithelial tissue types can also produce GM-CSF.  This small glycomeric protein is responsible 
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for the recruitment and production and function of macrophage and neutrophils, as well as 
eosinophils65.  GM-CSF signals via the JAK2/STAT5 pathway, although the cell-specificity of 
GM-CSF signaling is intriguingly complex66.  STAT5 is encoded by two separate genes resulting 
in two isoforms, STAT5A and STAT5B.  STAT5A-/- mice have a defect in bone marrow GM-
CSF-induced proliferation while STAT5B is known to play a role in growth hormone 
regulation50.  However, partially distinctive functions for the two isoforms during 
monocyte/macrophage differentiation have been suggested, again highlighting the cell-
specificity of STAT5 signaling66,67.  A recent study performed in a human leukemic cell line 
demonstrated chronic STAT5A signaling as a promoter of M1 macrophage differentiation. High 
IL-6 production along with enhanced activity of NF-κB was critical for this STAT5A dependent 
differentiation68.  Furthermore, GM-CSF is known to promote the accumulation of MDSCs in 
the tumor microenvironment69, validating our interest in the role of GM-CSF in the lung. 
In the lung GM-CSF is critical for homeostasis70,71, as its absence results in alveolar 
proteinosis.  It is also critical for alveolar macrophage development and function72.  A basal level 
of GM-CSF is present at all times in the lung, a major source being epithelial cells65,71, and it has 
been shown to augment signaling pathways downstream of TLR4 via augmentation of LPS-
induced Akt and Erk1/2 signaling73.  GM-CSF was found to be important for the second wave of 
LPS-TLR4 induced signaling pathways and nuclear localization of NF-κB (p50/65) augmenting 
neutrophil influx into the lung.  Furthermore, neutralization of GM-CSF resulted in lower 
physiological expression of TLR4 and decreased TNF-α levels following LPS administration, 
also resulting in decreased neutrophil recruitment74.  Taken together, these studies reveal the 
importance of GM-CSF signaling in the lung, regulating the ability of LPS to trigger a robust 
inflammatory response.  
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1.2.4 IL-6 and STAT3 signaling in MDSC differentiation, function, and lung homeostasis.   
Interleukin-6 (IL-6) was initially cloned as an interferon species 75,76, and called by a number of 
names including B-cell stimulatory factor 2 (BSF-2) 77, interferon-β2 (IFN-β2)75, and 26-kDa 
protein78.  First recognized as a B-cell proliferative factor79, it is now has an appreciated, yet 
complex, role in affecting numerous cell types under many disease conditions.  Although 
initially thought of primarily as an inflammatory cytokine, it has been reported that levels of pro-
inflammatory cytokines, TNF-α and MIP-2, are higher in the lungs of IL-6-/- following LPS 
exposure suggestive of a regulatory function at least in certain circumstances80.  IL-6 is also an 
important regulator of Th2 inflammation81.  Furthermore, evidence of IL-6 as a regulatory 
cytokine is demonstrated by the fact that IL-6-/- mice succumb during hyperoxic conditions 
within 96 hours82.  The emerging role of IL-6 as a regulatory cytokine, along with its role in B-
cell proliferation, points towards it being a major regulator of cytokine networks and thus a 
significant player in cellular differentiation. 
Jak2/STAT3 signaling is involved in tumor-associated MDSC generation83, and it has 
been shown that the presence of IL-6 with concomitant activation of STAT3 inhibits DC 
maturation resulting in the formation of an immature myeloid cell population4.   In vitro 
inhibition of STAT3 abolishes MDSC-suppressive activity, and blocking STAT3 in vivo 
abrogates MDSC expansion in tumor-bearing mice1.   
Because STAT3 is now recognized as the major regulator of tumor MDSC, it can be 
appreciated that cytokines and molecules that themselves induce STAT3 activation could also 
modulate MDSC accumulation and function and there are several examples of this concept in the 
literature.  For example, tumor derived Hsp72 regulates immunosuppressive functions of 
MDSCs via STAT384.  S100A9, which is regulated via STAT3, has also been shown to favor 
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MDSC differentiation33.  Modulation of STAT3 via miR-17-5p and miR-20a also alleviates the 
suppressive potency of MDSC85.  Furthermore, G-CSF, M-CSF, GM-CSF, and VEGF can all 
activate STAT3 and these have been linked to MDSC expansion1, and STAT3 promotion of 
CXCL1 by hepatocytes is an indirect way by which STAT3 directs MDSC accumulation86. 
Lastly, continual signaling through STAT3 by IL-6 induces up-regulation of the SOCS3 
protein, which has been shown to be a regulator of IL-6 signaling, and SOCS3 is a known 
modulator of cellular differentiation41,87.  
1.2.5 STAT1/STAT3 Crosstalk 
Although the role of STAT3 is well appreciated in MDSC biology, STAT1 is another 
transcription factor known to regulate the immunosuppressive function of MDSCs via promotion 
of nitric oxide.  Responsible for the regulation of nitric oxide synthase (iNOS), the ability of 
MDSC to suppress T cell activation is compromised in the absence of STAT13.  STAT1 is the 
main transcription factor transducing signals via IFNγ, a major cytokine involved in Th1-
associated host defense88.  Cross-regulation between Th1 and Th2 cytokines is well appreciated 
in the literature and recent evidence suggests that downstream interaction between STAT 
molecules, primarily STAT1 and STAT3, is partially responsible89,90. 
STAT1 and STAT3 compete for binding to the interferon gamma receptor 1 (IFNGR1) 
and STAT3 phosphorylation is stronger and more prolonged in STAT1-null cells90.  
Additionally, overexpression of a constitutively active STAT1 mutant protein can enhance IFNγ-
induced anti-proliferative activity91,92.  In contrast, IFNγ can induce the proliferation and survival 
of primary bone marrow cells from STAT1-null mice but not WT, revealing the presence of an 
alternative signaling pathway downstream of IFNγ which takes over in the absence of STAT1 
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and which renders IFNγ proliferative rather than anti-proliferative.  Also, SOCS1 is a regulator 
of IFNγ induced responses by virtue of its activity in inhibiting STAT193.  SOCS1-/- mice are 
hypersensitive to LPS-induced endotoxic shock suggesting the need to regulate STAT1 signaling 
in the presence of LPS94,95. 
STAT1 signaling has been shown to inhibit IL-10 in a variety of models96-98, 
demonstrating the suppressive nature of STAT1 on production of this regulatory cytokine.  Most 
interesting to our studies is the role of STAT1 in the regulation of LPS-induced inflammation.  
Aryl hydrocarbon receptor (AhR) was shown to interact with STAT1 to inhibit production of IL-
6, a known inducer of MDSC differentiation and function via STAT34,99. 
1.3 THE COORDINATION OF EARLY AND LATE PULMONARY HOST 
DEFENSE 
The development of regulatory myeloid cells in the lung, now recognized as lung MDSCs, in 
response to bacterial endotoxin instinctively prompted the investigation of their possible role in 
host defense against Gram negative pathogens.  We chose to use Klebsiella pneumoniae as our 
model, given that K. pneumoniae is a common isolate found in nosocomial infections and its 
potency as an opportunistic pathogen in the lung results in a high rate of mortality and 
morbidity100,101.    
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1.3.1 The four phases of host defense 
To quote Rodger P. McEver:  “There is a delicate balance between initiating inflammation to 
control microbial invasion and dampening inflammation to prevent untoward tissue injury.”  102.  
This quote describes Mantovani’s work on long-pentraxin 3 (PTX3)103, a molecule which acts as 
a molecular switch to either enhance or diminish neutrophil influx into the lung104.  In the 
context of host defense against K. pneumoniae, PTX3 has been described as having seemingly 
contradictory functions whereby, depending on the degree of infection, it may increase or oppose 
the recruitment of neutrophils into the tissue.  Although just one example, these observations 
highlight the complexity of a robust innate immune response because although necessary for 
protection against microbial pathogens, the resolution of inflammation and restoration of tissue 
homeostasis is equally important.  Control of inflammation must be carefully coordinated, the 
complexity of which is only starting to be understood. 
 The innate immune system response can be broken down into four phases, all of which 
must occur for successful host defense105.  Phase I is triggered by the initial recognition of 
pathogen by patrolling antigen-presenting cells (APCs).  These APCs provide chemotactic 
signals, which trigger neutrophil egress from the bone marrow and into the tissue.  Phase II 
occurs as the neutrophils reach the site of infection, degranulate, and trigger further monocyte 
extravasation.  Phase III is a delicate balance of signal recognition between the APCs and 
neutrophils.  Neutrophils have a short life span and rapidly begin to undergo apoptosis at the site 
of inflammation, somewhat aided by signals provided by macrophages. These apoptotic 
neutrophils in turn trigger a regulatory program in the macrophages, including the production of 
interleukin-10, which prevents further neutrophil infiltration.  Phase IV is the result of a properly 
functioning Phase III, where the interaction with and clearance of apoptotic neutrophils by 
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macrophages further accentuates anti-inflammatory activity of macrophages in order to restore 
homeostasis.    
 The sub-populations of macrophages, as defined by location within particular tissues, 
which play a roll in neutrophil recruitment and/or elimination are not yet well understood and 
this topic remains largely unexplored in the literature106. 
1.3.2 Innate Host Defense Against Klebsiella pneumoniae  
Bacterial pneumonia is a leading cause of morbidity and mortality worldwide causing 40,000 to 
70,000 deaths annually.  K. pneumoniae, a Gram negative bacterium with lipopolysaccharide as 
a major component of its cell wall, is a commonly isolated causative agent of pneumonia in 
hospital-acquired infections101.  
Innate host defense against K. pneumoniae has been shown to involve both alveolar 
macrophages (AMs), the resident phagocytes in the alveolar space, and neutrophils (PMNs).  
AMs, due to their anatomical location serve as the first line of cellular host-defense against K. 
pneumoniae.  Both experiments where neutrophil influx was decreased, as in the case of TIRAP-
/- mice in comparison to WT, or experiments where neutrophil influx was increased, as induced 
by over-expression of KC, demonstrate the crucial role of neutrophils in bacterial killing107 108.  
Selective depletion of AMs has been attempted through the use of intratracheal administration of 
liposomes containing dichloromethyene diphosphonate, or DMDP109. Braoug-Holub and 
colleagues depleted AMs using DMDP-liposomes and revealed that AMs are a critical 
component of host defense against K. pneumoniae110.  In AM-depleted animals, enhanced 
neutrophil recruitment and MPO activity, which corresponded with increased levels of TNF-α 
was observed.  Strikingly, in spite of increased neutrophilia, enhanced bacterial burden was 
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evident in both the lungs and plasma of AM-depleted animals suggesting that neutrophils alone 
are not sufficient for bacterial clearance.  AM depletion in the case of a sub-lethal dose of 100 
CFU K. pneumoniae suggests that not only do AMs participate in initial host defense, but that 
signals provided by the AMs enhance neutrophil killing capacity.  In our studies we also noted 
that in the case of 100 CFU K. pneumoniae, neutrophil recruitment is minimal, presumably due 
to rapid clearance of bacteria by the AMs.  
Recognition of K. pneumoniae occurs via the TLR4/MyD88 signaling pathway and 
TLR4, involving both the MyD88 and TRIF dependent pathways111-113.  Functional TLR2 and 
TLR4 expression is required for adequate host defense suggesting cooperation between these two 
signaling pathways114. 
Downstream of TLR ligation and signaling, NF-κB activation serves to promote the 
release of TNF-α, MIP-2, and KC, three critical cytokines for protection against K. pneumoniae.  
All three play a role in neutrophil recruitment, and while MIP-2 is a C-X-C chemokine that aids 
in neutrophil recruitment, TNF-α is also linked directly to macrophage activation115.  Nitric oxide 
is also critical for host defense against K. pneumoniae as demonstrated by increased bacterial 
survival in the presence of L-NAME, an inhibitor of iNOS116, and interleukin-17 (IL-17) also 
plays a roll in enhanced neutrophil recruitment and TNF-α induction117. 
There is evidence that neutrophils aid in killing of K. pneumoniae118.  However, the 
neutrophil influx induced by K. pneumoniae can be followed by extensive lung destruction if left 
unchecked119.  Furthermore, although the role of AMs is well appreciated, the cells involved in 
host defense in the lung interstitium are not well defined.  
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1.3.3 Alveolar Macrophages vs Tissue Macrophage Subsets 
Interactions between subsets of antigen-presenting cells (APCs) within the respiratory tract are 
an important determinant of the immune response in the lung120. Macrophage and DC subsets 
must cooperate to properly modulate an immune response to invading pathogens, innocuous 
substances, and inhaled allergens2. 
 With meticulous dissection, von Garnier and colleagues utilized flow cytometry of cells 
within the parenchymal tissue, the conducting airways, and the bronchial alveolar lavage fluid 
(BALF), to reveal differing subsets of APCs within the respiratory tract based on anatomical 
location120.  Dual staining with antibodies against CD11c and MHC II was used to discern the 
presence of four subsets, which differed in their frequency between tissue, airway, and BALF.  
The four subsets consisted of cells that were CD11cnegI-Ad high(R1), CD11chighI-Ad high(R2), 
CD11cint-highI-Ad low(R3), CD11cintI-Ad neg(R4).  R1 and R2 were found in both the parenchyma 
and the conducting airways, while R3 and R4 were largely located in the parenchymal lung 
tissue.  Strikingly, one of these subsets (R3) located predominantly within the lung parenchyma, 
characterized by intermediated expression of CD11c and low expression of MHC II bore close 
resemblance to lung MDSCs although no function was attributed to them at that time. 
 AMs present within the alveolar space are known to regulate immune responses, and in 
2009, a role for interstitial macrophages (IMs)121 in the suppression of Th2 inflammation has 
been documented122.  However, although there were similarities between the lung MDSCs we 
have described5 and the IMs in this report, the latter were not found to be Gr1int, nor did they 
express CD11c.  It is worth noting that the characterization of IMs was performed on lungs from 
naïve animals inviting speculation as to what the phenotype of IMs would be in LPS treated 
animals.  It is likely that due to the heterogeneity of lung MDSC-like cells36, IMs may be one 
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cellular component.  However, their generation in situ in response to LPS was not examined.  
Therefore, it is not known whether or not IMs develop from trafficking lineage negative 
precursors as previously demonstrated5. 
Finally, control of neutrophil numbers maintained in part by alveolar macrophages under 
steady-state conditions is a critical component of lung homeostasis123.  Alveolar macrophages, 
through a process known as efferocytosis, or the phagocytosis of apoptotic cells, participate in 
the removal of dying neutrophils from the alveolar space124.  Although efferocytosis (described 
in greater detail in Section 1.3.7) by macrophages has also been investigated in vitro125,126, 
macrophage populations within the interstitium have not yet been explicitly recognized as 
efferocytic cells. 
1.3.4 STAT1 in host defense 
The use of embryonic stem cells deficient in STAT1, as well as STAT1-/- mice, revealed that 
this molecule is essential for anti-viral immunity and responsiveness to IFNα and IFNγ as 
evidenced by the fact that 100% of animals succumbed by 5 days post infection with L. 
monocytogenes or vesicular stomatitis virus88,127.  STAT1 is the main transcription factor 
induced downstream of IFNγ96, is responsible for eliciting macrophage activation128, and is a 
major player in the induction of inflammatory responses129.  Interestingly, IFNγ induced STAT1 
is augmented when cells are simultaneously or pre-exposed to LPS, highlighting the role of 
STAT1 as a central effector molecule for macrophage function during host defense against Gram 
negative pathogens.  Of relevance, the role of STAT1 in host defense against K. pneumoniae has 
not been explored, although STAT1 is a critical molecule for the regulation of iNOS induction 
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and nitric oxide production88, which are known to be important for protection against K. 
pneumoniae130. 
STAT1 also plays a role in expression of chemokines in the lung, regulating not only 
macrophage activation via IFNγ, but also cellular recruitment131.  Of note, freshly isolated 
monocytes stimulated with IFNγ are not available to migrate in response to CCL2, therefore 
IFNγ-STAT1 signaling has a negative regulatory effect on monocyte chemotaxis132. 
1.3.5 Neutrophils 
Neutrophils are the most abundant white blood cell in the circulation and are rapidly recruited to 
sites of infection.  Highly phagocytic, they are crucial for host defense based upon their strong 
anti-microbial properties via the production of antimicrobial peptides, serine proteases, and large 
amounts of reactive-oxygen species (ROS)133,134.  The number of neutrophils present in the 
circulation at any one time has been described as being the result of a combination of generation, 
recruitment, survival, and removal133. 
Neutrophils are consistently generated in the BM, and in the steady state, about 1-2% are 
released from the BM.  Because their half-life is less than 6 hours in the circulation, this is 
adequate in order to maintain peripheral homeostasis135.  It is critical that during homeostatic 
conditions, neutrophil removal matches their production133 since many of the anti-microbial 
effectors produced by neutrophils can inflict tissue damage119.   
G-CSF is the principal cytokine for neutrophil development, and both G-CSF-/- and G-
CSFR-/- mice have compromised basal levels of granulopoiesis136.  Apart from G-CSF, other 
cytokines, such as GM-CSF137 and IL-6138 can stimulate granulopoiesis in vivo.  Furthermore, 
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IL-6 and TNF-α regulate neutrophil function139 inducing their migration and activation at the site 
of infection80. 
Neutrophils can be identified microscopically in the lungs by their distinctive multi-lobed 
nuclei (based on histological examination following Wright’s stain), and phenotypically by 
expression of characteristic surface molecules such as Gr1 (both Ly6Ghi and Ly6C expressing), 
CD11b, CD62L, and CXCR2135. 
1.3.6 Neutrophil Recruitment in Response to K. pneumoniae. 
Deficiencies in neutrophil recruitment are linked to increased host susceptibility during K. 
pneumoniae infection140.  Conversely, increasing neutrophil recruitment has proven to be 
beneficial108.  During host defense, neutrophils are recruited from the bone marrow to the site of 
inflammation.  Transendothelial migration of leukocytes from the blood to sites of inflammation 
includes several key steps including, rolling, adhesion strengthening, intraluminal crawling, 
paracellular or transcellular migration, and migration through the basement membrane.  Integrins 
and selectins are the major adhesion molecules regulating each of these aspects of neutrophil 
emigration141.  
The most crucial neutrophil chemoattractants are CXC chemokines including IL-8 
(CXCL8) (present in humans but not in mice), MIP-2 (CXCL2) and KC (CXCL1) (present in 
both humans and mice)142.  Both MIP-2 and KC signal through the receptor CXCR2, and also 
play a role in neutrophil activation after they arrive at the site of infection.  
CXC chemokines act on neutrophils to affect their release from the BM as well as at 
multiple steps of neutrophil migration. CXC chemokines such as KC can desensitize the 
responsiveness of neutrophils to SDF-1, therefore disrupting the BM SDF-1/CXCR4 retention 
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signaling and thus facilitating neutrophil egress143.  MIP-2 and KC are each capable of inducing 
a dose and time-dependent increase in neutrophil rolling on endothelial cells, which was 
inhibited by anti-P-selectin antibody, suggesting that these chemokines induce a P-selectin-
dependent rolling144.  In vivo studies further confirmed that CXCR2, the receptor for KC and 
MIP-2, was required for neutrophil tight adhesion to inflamed venules145.  Recent work in our 
laboratory has also demonstrated that TNF-α and IL-17 contribute to neutrophil recruitment and 
survival in the lung146. 
A previous report from our laboratory implicated RANTES in neutrophil accumulation in 
the lungs147.  Interestingly, we observed decreased RANTES expression in STAT1-/- lung tissue 
following infection with K. pneumoniae and STAT1 regulation of RANTES-induced 
neutrophilia may be one reason we observe decreased neutrophils in STAT1-/- mice (See 3.0).  
Finally, it is interesting to note that we detected substantial levels of these neutrophil recruiting 
chemokines in culture supernatants of purified lung-MDSCs (data not shown).  Therefore, it may 
be that lung MDSCs participate in neutrophil/macrophage recruitment for necessary host 
defense, while simultaneously being a source of tissue IL-10 for the tempering of inflammation. 
1.3.7 Neutrophil Apoptosis and Clearance (Efferocytosis) 
Neutrophils release oxidants, necessary for bacterial killing, but if left unchecked, these oxidants 
and enzymes can cause tissue damage119,148.  In the absence of inflammation, circulating 
neutrophils are quickly removed with a half-life of 6-8 hours149, and this normal turnover is 
accomplished through constitutive apoptosis, followed by clearance by macrophages150 by a 
process is referred to as efferocytosis meaning ‘to carry the grave’133. Neutrophil apoptosis is 
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critical for the resolution of inflammation, but host-derived factors (such as GM-CSF and G-
CSF) and microbial products can delay neutrophil apoptosis105.  
During apoptosis, neutrophils shed receptors and are functionally compromised, no 
longer secreting pro-inflammatory cytokines, and therefore becoming anti-inflammatory instead 
of pro-inflammatory upon recognition by a macrophage.  Indeed, the production of IL-10, PGE2 
and TGF-β has been linked to macrophage recognition of apoptotic neutrophils105,124.  In order 
for a neutrophil to be recognized, it must express appropriate molecules on its surface, such as 
bridge molecules and signaling receptors including phosphatidylserine (PS), cardiolipin, CD14, 
PTX3, and CD43133.  These molecules are recognized by scavenger receptors on macrophages 
such as CD36 (recognizes PS), ICAM3 (recognizes CD14), nucleolin (recognizes CD43) and 
CD91 (recognizes PTX3).   
CD14 is a GPI anchored surface molecule, and is part of the LPS/LBP complex, found on 
the surface of monocytes and macrophages.  The soluble form of CD14 aids LPS recognition by 
CD14 negative cells.  Importantly, bacterial phagocytosis via CD14 is independent from FcγR-
mediated phagocytosis.  Recently IL-10 was shown to enhance CD14-mediated uptake of 
apoptotic cells151, and this recognition of apoptotic cells via CD14 can protect against LPS-
induced shock152. Of note, IFNγ was found to have the opposite effect153. 
CD36 has been shown to bind multiple ligands including phospholipids, long-chain fatty 
acids, and sickle cell erythrocytes154.  Expressed on a variety of cells types it is defined as a class 
B scavenger receptor, and importantly, CD36-/- mice exhibit up to 80% reduction in OxLDL 
binding and uptake155.  Furthermore, DCs employ CD36 during cross-presentation of apoptotic 
cell antigens to induce CTL activation156. 
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Several other scavenger receptors, some newly identified have also been reported.  The 
urokinase receptor (uPAR/CD87) negatively regulates efferocytosis and uPAR-/- macrophages 
have increased efferocytic ability157 as well as an enhanced capacity to engulf viable neutrophils.  
Park et al. demonstrated that uPAR/uPA binding enhanced phagocytosis by either macrophages 
or neutrophils and that uPAR expression on one of the two cell types was necessary.  uPAR 
expression seems to inhibit integrin binding to uPAR on nearby cells157.  Previously, IL-10 was 
shown to inhibit uPAR expression, a plausible mechanism contributing to the ability of IL-10 to 
promote efferocytosis158.  Urokinase and its receptor are implicated in migration of monocytes 
and adherence to both fibrinogen and vitronectin, which is critical for immunity/inflammation. 
Rac1 and Cdc42 signaling (both small GPTases) are regulated by IFNγ and IL-10.  IFNγ 
activates Rac1, decreasing the amount available for F-actin remodeling, a necessary mechanism 
during phagocytosis of FcγR-mediated internalization of IgG opsonized particles.  IL-10 
stimulation increases FcγR expression 159.  Interestingly signaling via the macrophage G-protein-
coupled receptor G2A regulates enhanced efferocytosis via augmentation Rac1 signaling160.  The 
opposition of these two studies could point to the critical control of Rac1 signaling during 
phagocytic events, dependent upon the type of cargo and state of the surrounding 
microenvironment.  Additionally, the binding of phosphatidylserine (PS) on dying cells and 
subsequent efferocytosis, likely employs different mechanisms than FcγR-mediated 
internalization. 
Taken together, the interplay between neutrophils and macrophages is a complex process.  
Enhanced understanding of these processes will lead to therapeutic development to prevent lung 
injury following bacterial pneumonia. 
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1.4 INTERLEUKIN-10 
Interleukin-10 (IL-10) is a potent regulatory cytokine.  Discovered in 1990 by Mossman and 
colleagues161, it was found to suppress not only Th1 responses, but also curb inflammation by 
limiting activation of a variety of cell types89.  Of importance for our studies, IL-10-/- mice 
develop inflammatory bowel disease162, suggesting that IL-10 functions, at least in part, in a non-
redundant manner as a regulator of inflammation. 
1.4.1 Early vs. Late IL-10 production in host defense 
Numerous studies have demonstrated the negative impact of IL-10 on host defense124,163-165.  In 
all of these cases, IL-10 was shown to inhibit the initial host response to infection.  Given the 
potency of IL-10 as an anti-inflammatory cytokine, these results are not surprising.  In the case 
of infection with K. pneumoniae, neutralization of IL-10 prior to infection proved to be 
beneficial and resulted in increased bacterial clearance165.  Similar results were shown with 
Pseudomonas aeruginosa166.  In the case of both of these infections, high IL-10 was detrimental 
to the host due to impairment of neutrophil recruitment via suppression of neutrophil attracting 
chemokines.  However, in order to prevent tissue injury to maintain organ function, 
inflammation must not be permitted to continue in an uncontrolled manner102.  As demonstrated 
in the case of infection by Pneumocystis carinii, treatment with viral IL-10 was beneficial and 
decreased tissue inflammation without altering pathogen clearance167.  In a sepsis model it was 
demonstrated that a balance of pro and anti-inflammatory cytokines is necessary168.  The authors 
showed that severe sepsis, which results in greater mortality than moderate sepsis, was due to 
unopposed inflammatory responses.   
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These studies suggest a role for IL-10 in appropriate resolution of inflammation.  
Although there is a recognized need for such regulation, an interstitial cellular source of IL-10, 
which may aid in homeostatic resolution, has not been identified.  A review article published in 
the Journal of Immunology in 2008 put it well by stating that although many cell types can 
produce IL-10, “the priming of these various populations during infections is not well understood 
and it is not clear whether the cellular source of IL-10 dictates its cellular target and thus its 
outcome”169. 
1.4.2 IL-10 production by myeloid cells 
Because of the potent anti-inflammatory properties of IL-10, its production by innate cells is 
regulated at multiple levels including changes in chromatin structure, regulation of transcription 
factors and their activation, and post-transcriptional modifications170.  In addition, positive or 
negative regulation of IL-10 can be influenced by multiple soluble factors. The complexity of IL-
10 regulation makes comprehensive assessment of all of its functions   difficult171. 
Microbial products induce IL-10 secretion from DCs and macrophages, and although 
these cells as well as MDSCs are all known to produce IL-10, neutrophils have also recently 
been reported to express IL-10 in vivo172.  Upon TLR ligation, both MyD88-dependent and 
independent (TRIF) pathways are involved in promoting the production of IL-10171.  
Downstream of MyD88, both the MAPK/ERK cascade and NF-κB family members induce IL-
10 transcription.  The amount of ERK activation, a MAPK family member, dose dependently 
regulates production of IL-10 by DCs and macrophages173.  Additionally, activation of p38 
kinases can trigger IL-10 production, and both ERK and p38 dependent IL-10 expression can be 
dampened by IFNγ174.  In brief, the release of GSK3 is typically held in check by PI3K, but 
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because IFNγ negatively regulates PI3K, GSK3 is released to subsequently act by inhibiting 
binding of activator protein 1 (AP1) to the IL-10 promoter significant since the activity of AP1 
on the IL-10 promoter induces IL-10 transcription downstream of TLR174.  Interestingly, IL-10 
also regulates its own production by promoting dual-specificity protein-phosphatase 1 (DUSP1), 
a p38 regulator175, and a second wave of IL-10 production from myeloid cells has been attributed 
to type I IFNs via TRAF3 signaling176.  Various studies have revealed that C/EBPβ, STAT3, and 
IRF1 can all bind to the IL-10 promoter to induce IL-10 transcription171.  With regard to NF-κB 
family members, NF-κB p50 deficient mice display reduced IL-10 expression177.   
The production of IL-10 is also regulated by a number of soluble factors.  LPS has been 
shown to induce IL-10 expression by triggering release of IL-27 and type I IFNs, a process 
dependent upon IL-27 activation of both STAT1 and STAT3178.  IFNγ can cross-regulate IL-10 
the effects of IL-10, not only its production.  IFNγ was shown to switch the balance of STAT 
activation by IL-10 from STAT3 to STAT1 in the presence of IFNγ98, and in fact, IL-10 only 
triggered STAT1 when IFNγ was present.  Due to the centrality of STAT3 in MDSC biology, 
STAT3 regulated IL-10 production is of special interest.  
IL-27 and IL-6 trigger the production of IL-10179, and given that GM-CSF can promote 
IL-6 production180, GM-CSF activation of STAT proteins likely regulates both IL-6 and IL-10 
production to direct immune outcome.  Of great interest, GM-CSF blocks STAT1 activation 
downstream of IFNs (IFNα and IFNγ)181, suggesting that some of the observed effects of GM-
CSF in our model (Further discussed in Section 2.0) may be a result of STAT1 inhibition. 
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1.4.3 IL-10 contributes to Neutrophil Clearance and Resolution of Inflammation 
The resolution of inflammation (Phase III-IV of host defense as described in Section 1.3.1) is 
characterized by removal of apoptotic neutrophils and a shift in pro-inflammatory mediators to 
anti-inflammatory signals, some of which are lipoxins, protectins, and resolvins.  How exactly 
this switch occurs is an area of ongoing investigation, but is thought to involve the production of 
protectins by macrophages that have engulfed apoptotic neutrophils, and lipoxins appear to play 
a role in discontinuing neutrophil influx to the site of infection106,182,183.   
Ample evidence regarding the immunobiology of IL-10 points to it being a central 
regulator of inflammation, not only for the prevention of autoimmune disease, development of 
regulatory T-cells and DCs, and dampening of Th2-allergic inflammation, but now for the 
resolution of inflammation following bacterial pneumonia.  IL-10 plays a role in dampening 
neutrophil influx and function by counter-regulating TNF-α, KC, RANTES, and MIP-2 
production165,184-187, and recent studies report IL-10 release during efferocytosis124. 
The role of IL-10 in regulation of efferocytosis is of considerable interest.  Michlewska 
and colleagues demonstrated that ingestion of apoptotic cells by IL-10-/- bone marrow 
macrophages is markedly reduced as compared to WT, suggesting a role for IL-10 in the 
promotion of efferocytosis126.  LPS and TNF-α are known inhibit neutrophil apoptosis188,189, but 
this inhibition can be counteracted in the presence of IL-10 suggesting that the presence of IL-10, 
even in low levels, dampens the inflammatory effects of both LPS and TNF-α126,185. 
IL-10 has also been shown to maintain FcγR expression for the function of FcγR 
mediated phagocytosis, suggesting that IL-10 can play a positive role in the internalization of 
IgG coated particles with implications for host defense190.  Due to its regulatory properties, IL-10 
may promote phagocytosis to prevent exacerbated inflammatory cytokine release but how 
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exactly this process occurs is not known.  As indicated above, IL-10 plays a role in the regulation 
of several scavenger receptors but details of their engagement and role during efferocytosis is an 
area of ongoing investigation.   
There is much interest in further understanding the mechanisms that may regulate MDSC 
accumulation and function in different disease settings.  Due to our discovery of a lung MDSC-
like cell in response to LPS5, the following data explore mechanisms by which LPS/TLR4 
signaling contributes to their generation, including the role of GM-CSF, a central growth factor 
in lung biology.  Furthermore, how neutrophil influx and clearance is regulated is of increasing 
interest since the deleterious effects of neutrophils in the induction of lung injury are being 
increasingly recognized.  The following data uncover the role of GM-CSF/STAT5A signaling in 
lung MDSC development, and reveal a yet unrecognized role of STAT1 as a negative regulator 
of MDSC accumulation.  Furthermore, we investigated a cellular mechanism that regulates 
neutrophil clearance in the lung interstitium, an area unexplored in the literature to date.  
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2.0  THE DEVELOPMENT OF A LUNG MDSC-LIKE CELL 
2.1 ABSTRACT 
Our laboratory has studied the effects of lipopolysaccharide (LPS) exposure on the murine lung 
as well as on bone marrow progenitor cells in vitro. These studies initially led to the discovery 
that intratracheal administration of LPS, a toll-like receptor 4 (TLR4) ligand, induces the 
appearance of suppressive CD11b+Gr1intF4/80+ MDSC-like cells in the lung, which secrete nitric 
oxide (NO), Arginase-1, interleukin-6 (IL-6), interleukin-10 (IL-10) and granulocyte 
macrophage colony-stimulating factor (GM-CSF).  Furthermore, the secretion of IL-10 and Arg-
1 in combination with NO, serves to suppress Th2-driven inflammation.  Therefore, pulmonary 
MDSC-like cells likely help to control inappropriate inflammatory responses in the airways5, and 
thus may be a potential mechanism underlying the hygiene hypothesis.  
This present work expands upon these initial findings to illustrate that GM-CSF and LPS 
act in concert to induce MDSCs in vitro from lineage-negative progenitor cells.  GM-CSF is 
known to strengthen signaling downstream of TLR4, and is also linked to IL-6 production in a 
variety of cell types.  These studies were carried out in vitro, but importantly, it was also found 
by in vivo neutralization of GM-CSF that it is similarly required for the development of 
functional MDSC-like cells in the lung.  Since GM-CSF is known to signal via STAT5, we 
observed a reduction in the CD11b+Gr1intF4/80+ population in STAT5A-/- mice upon exposure 
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to LPS, suggesting at least a partial dependence on GM-CSF-STAT5A signaling for their 
expansion.  These data strongly suggest that cooperation between GM-CSF and TLR signaling 
induces the development of lung MDSCs. 
2.2 INTRODUCTION 
Myeloid-derived suppressor cells (MDSCs) have historically been investigated largely in the 
context of cancer development and tumor growth1.  In contrast to a negative connotation of 
MDSCs in cancer where immune suppression has deleterious effects, pulmonary MDSCs may 
help to control inappropriate inflammatory responses to inhaled allergens and represent an 
important mechanism for the suppression of the initiation and perpetuation of asthma5.  These 
findings, published in 2010, are summarized below and in Figure 1.  
 
Figure 1. Schematic depicting regulation of lung-MDSC accumulation and function. 
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A relatively high dose of LPS inhalation induces the differentiation and expansion of lung trafficking HSPCs into a 
variety of innate cell types, including CD11b+Gr1intF4/80+ MDSC-like cells in the lung tissue.  In contrast to 
activated lung DC, these cells do not traffic to the draining lymph nodes which causes a 5–10-fold enrichment of 
these cells relative to DCs in the tissue. Molecules expressed by the CD11b+Gr1intF4/80+ cells such as arginase 1 and 
IL-10 suppress reactivation of Th2 cells by the resident DCs23. 
 
Allergic asthma is a chronic inflammatory condition of the lower airways, and is 
promoted by repeated interactions between allergen(s) and the immune system.  Although the 
presence of allergen is necessary for disease development and exacerbation, the prevalence of 
allergic disease has been paradoxically increasing in developed countries where exposure to 
allergens is reduced.  In light of this observation, the hygiene hypothesis was postulated in 1989, 
stating that early childhood exposure to pathogen-associated products, like endotoxin, may 
actually be protective against future allergic responses via the induction of immunological 
tolerance6.  It is established that bacterial endotoxin (lipopolysaccharide-LPS) has adjuvant-like 
properties and can promote an inflammatory response in the lung12,14,16. However, pulmonary 
LPS exposure has also been linked to immune suppression13, and importantly, findings by von 
Mutius et al. showed that endotoxin exposure was inversely correlated with development of 
asthma in children7. In an attempt to recapitulate the idea behind the hygiene hypothesis, our 
laboratory has studied the effects of LPS exposure on the murine lung as well as on bone marrow 
progenitor cells in vitro. These ongoing studies have led to the discovery that intratracheal 
administration of LPS, a toll-like receptor 4 (TLR4) ligand, induces the appearance of MDSC-
like cells in the lung, which secrete nitric oxide (NO), arginase 1, interleukin-6 (IL-6), 
interleukin-10 (IL-10), and granulocyte macrophage colony-stimulating factor (GM-CSF).  We 
have shown that signaling through the TLR4-MyD88 pathway results in this suppressive 
phenotype5.  Furthermore, MDSC secretion of NO, IL-10, and Arg-1, serves to suppress Th2 
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responses.  In vitro, GM-CSF induces conventional, myeloid-like DC (cDC) development, but 
the addition of LPS results in the generation of cells with suppressive function that are 
phenotypically similar to MDSCs found in vivo5.  This link between LPS exposure and MDSCs 
is intriguing in light of the hygiene hypothesis, prompting many questions regarding the role of 
both LPS and GM-CSF in their development.  We investigated the role of GM-CSF in the 
expansion of lung MDSCs in vivo, as well as the contribution of STAT5 signaling downstream 
of GM-CSF.  Our data strongly suggest a cooperative role for LPS and GM-CSF in MDSC 
development both in vivo and in vitro.  We now show that signaling mechanisms downstream of 
GM-CSF and TLR4 signaling are required for the full development of MDSC-like cells (Figure 
2).   
 
Figure 2: Generation of lung MDSC requires GM-CSF and LPS, signaling via STAT5 for the 
production of IL-6. 
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2.3 MATERIALS AND METHODS 
2.3.1 Animals and reagents 
Male 6- to 8-week old BALB/c ByJ or C57BL/6J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME).  DO11.10 transgenic mice were originally provided by Dr. 
Kenneth Murphy at Washington University (St Louis, MO) and were bred at the animal facility 
at the University of Pittsburgh. STAT5A-/- and IL-6-/- were purchased from the Jackson 
Laboratory (Bar Harbor, ME).  All studies with mice were approved by the animal care and use 
committee at the University of Pittsburgh.  Recombinant GM-CSF was purchased from 
PeproTech (Rocky Hill, NJ).  LPS from Escherichia coli, strain O26:B6, was obtained from 
Sigma (St. Louis, MO).  HDM (Dermatophagoides Pteronyssinus) was purchased from Greer 
Laboratories (Lenoir, NC) and was stripped of LPS using Endo-Trap columns.  A number of 
directly labeled monoclonal antibodies were used in cell phenotyping experiments as follows:  
phycoerythrin (PE)-labeled anti-mouse CD40 (clone 3/23), PE-labeled anti-mouse CD86 (clone 
GL1), APC-labeled anti-mouse CD11c (clone HL3), APC-labeled anti-mouse Gr1 (clone RB6-
8C5), fluoresceine isothiocyanate-labeled anti-mouse Ly6C (clone AL-21), PE-labeled anti-
mouse Ly6G (clone 1A8), and neutralizing anti-mouse IL-6, all purchased from BD Biosciences 
(San Jose, CA).  PE-labeled rat anti-mouse CD80 was purchased from Serotec (Raleigh, NC). 
PE-labeled anti-mouse major histocompatibility complex II (clone NIMR-4) was purchased from 
Southern Biotech (Birmingham, AL). PE- and APC-labeled anti-mouse F4/80 were purchased 
from Caltag Laboratories (Carlsbad, CA).  Neutralizing GM-CSF antibody (clone MP122E9) 
and isotype control Rat IgG2A were purchased from R&D Systems (Minneapolis, MN). 
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2.3.2 Induction of allergic airway inflammation by HDM 
BALB/c mice were exposed to HDM (100 µg per mouse per treatment) intratracheally on days 0, 
7, 13, and 21 with or without concomitant treatment with LPS (0.05-10 µg per mouse per 
treatment).  At 72h after the final HDM exposure, BAL fluid and lung tissue were obtained.  
Lung inflammation was gauged based upon BAL fluid differential cell counts by hematoxylin 
and eosin (H&E) staining.  Production of cytokines was assessed by preparation of whole lung 
homogenates and analysis by multiplex assay (Bioplex; Bio-Rad, Hercules, CA). 
2.3.3 Generation of LPS-induced cells in vivo 
LPS (up to 10 ug per mouse per dose) was instilled intratracheally in 100 ul into C67BL/6J or 
Balb/c daily for 3 or 4 consecutive days, respectively.  At 24h after the final exposure, mice were 
anesthetized with ketamine (100 mgkg-1)/xylazine (10 mgkg-1) mixture.  Brochial alveolar lavage 
fluid was obtained by inflating the lungs with 1mL phosphate-buffered saline (PBS), and then 
removing.  After exsanguinations through cardiac puncture, the aorta was severed and the 
pulmonary vasculature was perfused with sterile PBS to remove peripheral blood cells.  The 
perfused lungs were placed into C tubes associated with the AutoMacs Dissociator (Miltenyi 
Biotec), chopped twice using Program Lung_01, and incubated in an enzyme solution containing 
0.7 mg ml-1 collagenase A (Boehringer Mannheim (Roche), Indianapolis, IN) and 30 ug ml-1 
type IV bovine pancreatic DNase I (Sigma-Aldrich) for 45 min at 37’C.  Digested lungs were 
then removed from 37’C and subjected to program Lung_02.  Cells were then passed through a 
70 um cell strainer and the filtered cells were further enriched by positive selection using 
magnetic bead separation with anti-CD11b microbeads and an AutoMACs automated cell 
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separation instrument (Miltenyi Biotec, Auburn, CA).  CD11b+ cells were then stained with 
ApC-labeled anti-Gr1 and PE-labeled anti F4/80 antibodies (BD Biosciences).  Cells expressing 
F4/80 and an intermediate level of Gr1 (Gr1intF4/80+) were isolated by fluorescence-activated 
cell sorting using a BD Biosciences FACSAria flow cytometer running FACSDiva software. 
Conventional Dendritic Cells (cDCs) were isolated from mouse lungs.  Single cell lung 
suspensions were prepared as above except that magnetic bead selection was performed using 
anti-CD11c microbeads.  Then, CD11c+ cells, with low autofluorescence detected by the E PMT 
of the FACSAria cytometer, were sorted from highly autofluorescent cells (largely CD11c+ 
alveolar macrophages) and were used as cDCs. 
Cytokine production from CD11b+Gr1int cells was assessed by culturing the cells 
overnight at 37’C and then examining culture supernatants by multiplex cytokine assay (Bio-
Rad). 
2.3.4 Generation of DCs and CD11b+Gr1+ cells from bone marrow cells in vitro 
Femurs of mice were removed aseptically and cleaned of surrounding muscle tissue.  Bone 
marrow cells flushed from the femurs using PBS were grown in RPMI medium (Gibco, 
Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum (Gemini), 100 U ml-1 
of penicillin and 100 ug ml-1 of streptomycin sulfate (Gibco), 1 mM sodium-pyruvate (Gibco), 
and 50 uM 2-mercaptoethanol (Sigma, Carlsbad, CA).  The cultures were supplemented with 10 
ng ml-1 of GM-CSF in the absence or presence of LPS (Escherichia coli, strain O26:B6) and 
were incubated for 8-9 days at 37’C.  At the end of the culture period, non-adherent cells were 
collected and purified by magnetic bead positive selection (Miltenyi Biotec) for CD11c-
expressing cells in the case of cultures with GM-CSF alone, or for Thy1.2-expressing cells with 
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LPS plus GM-CSF-treated cultures.  Similar cultures were also started from lineageneg cells 
enriched using a lineage depletion kit (Miltenyi Biotec).  Cell purity, assessed by flow 
cytometry, was >95% in both the cases.  CD11c+ cells were considered to be conventional 
myeloid bone marrow DCs (BMDCs). 
2.3.5 Phenotypic evaluation of CD11b+Gr1int cells and cDCs 
The surface phenotype of cells was assessed by flow cytometry using standard methods.  In 
brief, cells were first incubated with unlabeled CD16/CD32 monoclonal antibody (Fc block) for 
5 minutes on ice, then with specifically conjugated monoclonal antibodies for an additional 15 
minutes.  In all cases, control staining with appropriate, matched isotype control antibodies was 
similarly performed.  All incubations were conducted at 4°C in PBS supplemented with 2% fetal 
bovine serum.  Analysis was carried out on a BD Biosciences FACSCalibur flow cytometer 
using CellQuest Pro software.  At least 10,000 events within the live cell gate were acquired for 
each sample.  Analysis was performed using FlowJo. 
2.3.6 Colorimetric assay for Nitric Oxide (NO) 
NO production by DCs and CD11b+Gr1int cells was quantified by measuring nitrite in culture 
supernatants using a commercially available colorimetric assay for nitrite determination (Griess 
Reagent Kit for Nitrite Determination, Molecular Probes - Invitrogen).   
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2.3.7 Neutralization of GM-CSF in vivo 
Neutralizing GM-CSF antibody (R&D Systems) was administered i.t. on days 0, 2, and 4 of 
lung-MDSC generation by 1 µg LPS i.t. days 1-4.  Lung MDSC-like cells were isolated from 
isotype or anti-GM-CSF treated mice and cultured ex vivo for 24 hours.  IL-6 was measured by 
ELISA.   
2.3.8 Statistical analyses 
Comparisons of means± s.d. were performed using one-way analysis of variance or Student’s t-
test using GraphPad Prism software (La Jolla, CA). Differences between the groups were 
considered significant if p < 0.05. 
 
2.4 RESULTS 
2.4.1 Lung MDSC-like cells expand in response to LPS in contrast to lung DC. 
We demonstrated the expansion of a suppressive CD11b+Gr1intF4/80+ cell in the lung in response 
to intratracheal LPS administration.  Although the presence of an MDSC-like cell could be 
detected 24 hours after LPS administration, the kinetics of this accumulation in combination with 
potency of cytokine production was not addressed.  Additionally, we observed a suppressive 
dominance of lung MDSCs over DCs ex vivo in co-culture experiments with T cells, but had not 
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quantified the numbers of both cell types side-by-side post LPS administration to determine if 
the ratios used ex vivo represented the physiological situation in the lung.  In order to accurately 
quantify lung MDSCs in vivo, we developed a 3-color staining scheme, depicted in Figure 3.  
Ongoing studies in our lab developed a method by which to quantify lung cDCs based on low 
autofluorescence, and dual staining with CD11c and major histocompatibility complex Class II 
(MHC-II) (Figure 4a-b).  Figure 5 reveals the actual frequency of these two cell types in the 
lung post-LPS administration.  Of note, alveolar macrophages (AMs) can be identified by high 
autofluorescence and high CD11c expression.  In Figure 4b a gate was drawn around the AM 
population to demonstrate how the percentage of AMs fluctuates in the lung following LPS 
treatment.  After 1 instillation of LPS, there was an observed increase, which decreases at 72 h 
post-LPS. 
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Figure 3. MDSC-like cells (Gr1int) expand in response to LPS. 
Mice were treated for 4 consecutive days with 1 µg LPS (schematic show).  Lung MDSC-like cells were 
identified by expression of CD11b, intermediate expression of Gr1, and expression of F4/80.  Data shown are 
representative of 3 independent experiments. 
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Figure 4. Lung dendritic cells are identified by low autofluorescence and MHCII expression, and 
their numbers decrease in the lung after LPS administration. 
Mice were treated for 4 consecutive days with 1 µg LPS.  (a) Lung DCs are identified by low autofluorescence and 
MHCII expression. (b) Lung DCs can be quantified by flow cytometric staining and are identified by low 
autofluorescence, CD11c expression and MHCII expression.  Data shown are representative of 3 independent 
experiments. 
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Figure 5. Ratio of MDSC:DC increases over time in the lung post LPS-treatment. 
Mice were treated for 4 consecutive days with 1 µg LPS.  Lung MDSC-like cells were identified using flow 
cytometry and expression of CD11b, intermediate expression of Gr1, and expression of F4/80.  Quantification was 
determined by back calculating to the number of total lung cells.  Lung DCs were identified by low 
autofluorescence, CD11c expression and MHCII expression and back calculated to the number of total lung cells.  
Data shown are representative of 3 independent experiments. 
2.4.2 Lung MDSC produce IL-10 and NO in a dose dependent manner. 
Because it is known that lung MDSC-like cells utilize both IL-10 and NO to suppress T-cell 
responses5, we investigated the production of these mediators from MDSCs isolated at various 
time points following LPS administration.  A high concentration of nitric oxide was noted in 
bone marrow cultures treated with GM-CSF + LPS, together which induced bone marrow 
MDSC development, in contrast to cultures with GM-CSF alone, which is known to promote DC 
development191.  Nitric oxide is known to be an inhibitor of cell proliferation192, which likely 
explains the lag in culture growth rate observed in the bone marrow cultures containing GM-CSF 
+ LPS (not shown).  Although there was an initial lag in proliferation, the GM-CSF and LPS 
promoted a robust expansion of bone marrow MDSCs by day 8-9 of bone marrow culture (see 
Figure 8). IL-10 and NO could be detected from bone marrow MDSCs, in higher amounts than 
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from BMDCs (not shown).  When soluble factor production by lung MDSCs was examined ex 
vivo, we observed that both IL-10 and NO production increased dose-dependently in response to 
LPS (Figure 6).  Lung-MDSCs isolated following 4 administrations of LPS produced more IL-
10 and NO on a per cell basis, than lung MDSCs isolated after just one LPS administration.  NO 
plays a role in endotoxin tolerance193, suggesting a role for lung MDSCs in the protection of lung 
integrity during high exposure to endotoxin.  The lungs of mice exhibited greater evidence of 
hemorrhagic damage after 1 day of LPS administration compared to 4 days, suggesting the 
development of some sort of tolerance mechanism.  It is interesting to consider that although the 
lungs of mice show less injury following 4 days of LPS treatment, higher amounts of NO were 
observed when 10 µg of LPS was used repeatedly in comparison to 1 µg LPS.  10 µg 
administration also correlated with increased weight loss (20% of body weight) suggesting that a 
large induction of NO may lead to the development of peroxynitrites194, known to be cytotoxic 
via induction of mitochondrial injury.  This is an area of future interest. 
 
Figure 6. MDSC-like cells (Gr1int) expand in response to LPS and produce IL-10 and Nitric 
Oxide. 
Mice were treated for 4 consecutive days with 1 µg LPS.  Gr1int were purified and cultured overnight at 37°C in 
RPMI+10% serum.  IL-10 and nitrite were measured in cell free supernatants by ELISA and Greiss assay, 
respectively.  These results are representative of 3 independent experiments. 
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2.4.3 High dose LPS is required to suppress HDM-driven eosinophilia. 
The robust expression of IL-10 in lung MDSCs isolated after 4 daily administrations of LPS is 
suggestive of a requirement for a high dose of LPS in the production of IL-10.  We previously 
showed that IL-10 was critical for the suppression of Th2 cytokines by MDSC5.  Others have 
shown that low levels of LPS exposure in combination with ovalbumin (OVA) antigen are 
correlated with the induction of Th2 driven eosinophilic inflammation, whereas a high dose of 
LPS is associated with a reduced Th2 response12.  Our data suggested that a threshold level of 
LPS exposure required for protection from Th2 was associated with MDSC development which 
was confirmed in vivo by adoptive transfer of lung or bone marrow MDSC into an OVA/CT 
model of allergic inflammation resulting in suppressed Th2-driven inflammation and pathology5.  
Using an HDM-driven model of allergic inflammation thought to more closely resemble 
naturally-occurring asthma, the threshold level of LPS required for induction of MDSCs and 
suppression of allergen-induced Th2 inflammation in the lung was investigated(Figure 7).  A 
high dose of LPS (10 ug) was required for the suppression of HDM-induced eosinophilic 
infiltration, which was quantified by examining cellular infiltrates in the bronchoalveolar lavage 
fluid. 
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Figure 7. Suppression of house dust mite (HDM)-driven eosinophilic inflammation in the 
airways by LPS. 
(a) Diagram of the treatment protocol.  HDM (100 µg per mouse) ±LPS (0.05-10 µg per mouse) was administered 
intratracheally (i.t.) at the indicated time points. After the final instillation, bronchoalveolar lavage (BAL) was 
performed with 1 mL PBS.  (b) Cellular differentials were determined following cytospin.  Values are mean ± s.d.  
These results are representative of 2 independent experiments (n = 4 mice per group). 
2.4.4 Lung MDSC-like cells can be generated from lineage negative progenitors in vitro. 
Since an MDSC-like cell phenotype could be generated from bulk bone marrow culture by the 
addition of GM-CSF + LPS, in contrast to bone marrow DC generation (GM-CSF alone) (Figure 
8 and Figure 9), the origin of these lung MDSC-like cells was investigated.  We sought to 
determine whether lineage negative progenitors could differentiate into MDSC-like cells, a 
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phenomenon that could have application for treatment of human conditions characterized by an 
aberrant Th2-biased immune response.  
 
Figure 8. MDSC-like cells can be generated in vitro under conditions of GM-CSF and LPS. 
Bone marrow cells were flushed aseptically from the femurs of WT mice.  The cells were cultured at a concentration 
of 1x106 cells/ml and were supplemented with 10 ng ml-1 of GM-CSF in the absence or presence of LPS 
(Escherichia coli, strain O26:B6).  On day 7, GM-CSF alone cultures were harvested and examined for phenotypic 
markers (BMDC). On day 9, GM-CSF+LPS cultures (MDSC) were harvested and cells were examined for 
phenotypic markers.  Results are representative of at least 4 independent experiments. 
 
Lineage negative progenitors were purified from the bone marrow of naïve mice and 
cultured under conditions of GM-CSF (10 ng/ml) or GM-CSF + LPS (1 µg/ml).  This experiment 
revealed that purified lineage negative progenitors could differentiate into MDSC-like cells 
essentially identical to those that developed from cultures of total bone marrow cells under 
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similar conditions (Figure 10a-b).  Furthermore, adoptive transfer GFP+ lineage negative cells 
intravenously, followed by i.t. LPS administration resulted in GFP+ cells in the lung with a 
CD11b+Gr1int phenotype, indicating that the in vivo precursor for MDSC may be lineage 
negative bone marrow progenitors that traffic to the lung via the peripheral circulation5.  
Collectively, these data suggest that generation of MDSCs is one critical aspect of how GM-CSF 
and LPS contribute to immune regulation of the fine balance between inflammation and 
tolerance in the lung.  
 
Figure 9. A triple positive (CD11b+Gr1intF4/80+) cell population is found with increased 
frequency in GM-CSF + LPS culture conditions. 
Bone marrow cells were flushed aseptically from the femurs of WT mice.  The cells were cultured at a concentration 
of 1x106 cells/ml and were supplemented with 10 ng ml-1 of GM-CSF in the absence or presence of LPS 
(Escherichia coli, strain O26:B6).  On day 7, GM-CSF alone cultures were harvested and examined for phenotypic 
markers (BMDC). On day 9, GM-CSF+LPS cultures (MDSC) were harvested and cells were examined for 
phenotypic markers.  Results are representative of at least 2 independent experiments. 
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Figure 10. MDSC like cells can be generated from lineage negative progenitors in vitro. 
LPS treatment generates CD11b+Gr1int cells from lineage negative progenitor cells. (a) The lineage negative 
population of bone marrow progenitor cells was enriched using a lineage depletion kit and phenotypic analysis was 
performed by flow cytometry.  (b) The lineage negative population of bone marrow progenitor cells was cultured 
with GM-CSF (10 ng/ml) in the absence or presence of LPS (1 µg/ml) for 9 days and phenotypic analysis was 
performed.  These results are representative of at least 3 independent experiments. Cells were pooled from 
individual mice prior to flow cytometric analysis. 
2.4.5 Neutralization of GM-CSF alters lung-MDSC cytokine profile. 
GM-CSF is critical for homeostasis in the lung microenvironment as its absence results in 
alveolar proteinosis48.  It is also critical for alveolar macrophage development and function72, 
and promotes differentiation of cDCs191.  A basal level of GM-CSF is present at all times in the 
lung, a major source being lung epithelial cells65,71.  GM-CSF being a critical growth factor, as 
well as an adjuvant48,195, was necessary for the development of a healthy and functional MDSC 
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like cell in vitro, which could be discerned from bone marrow progenitors based upon expression 
of Thy1.2, among other markers (Figures 8 & 10).  When LPS alone was added to cultures of 
bone marrow cells in the absence of GM-CSF, MDSCs did not develop based upon Thy1.2 
expression (Figure 11), and in fact, there were very few living cells left at the end of 6 days 
(data not shown).  These studies allowed us to observe that in the absence of GM-CSF, we did 
not achieve a cell type phenotypically similar to a MDSC. 
 
Figure 11. LPS alone does not generate a Thy1.2+ bone marrow MDSC-like cell. 
Bone marrow cells were flushed aseptically from the femurs of WT mice.  The cells were cultured at a concentration 
of 1x106 cells/ml and were supplemented with 1 µg/ml LPS (Escherichia coli, strain O26:B6).  On day 7, the 
cultures were harvested and cells were examined for phenotypic markers.  Results are representative of at least 2 
independent experiments.  Cells were pooled from mice prior to culture and flow cytometric analysis. 
 
Given the lack of bone marrow MDSC development in the absence of GM-CSF, we 
sought to determine whether neutralization of GM-CSF in vivo would result in a defect in lung 
MDSC development and/or function.  Based upon the work of Anderson and colleagues utilizing 
a model of GM-CSF neutralization during LPS administration73, we administered neutralizing 
GM-CSF antibody intratracheally 2 hours prior to LPS administration.  The basic model is 
shown in Figure 12a and antibody administration was found to be effective in neutralization of 
GM-CSF in the lung tissue (Figure 12b).  Strikingly, lung MDSCs produced reduced IL-6 and 
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increased NO (as quantified by measurement of nitrite) ex vivo when purified from animals 
treated with neutralizing GM-CSF antibody (Figure 12c).  Neutralization of GM-CSF also 
reduced dual expression of Gr1 and F4/80 in the lung tissue (Figure 13) further indicating that 
GM-CSF is an important cytokine for lung-MDSC generation. 
 
 
Figure 12. Neutralization of GM-CSF during LPS administration alters cytokine profile of lung 
MDSC-like cells. 
A neutralizing GM-CSF antibody (R&D Systems) was administered on day 1, 3 and 4 of LPS administration (1 
µg/mouse/day).  (a) Schematic of protocol.  On day 5, mice were harvested.  (b) GM-CSF was measured by ELISA 
in total lung homogenate.  (c) Gr1int were purified and put in culture overnight at 37°C.  IL-6 and nitrite were 
measured in cell free supernatants by ELISA and Greiss assay, respectively.  Results are representative of 3 
independent experiments.  Cells were pooled from mice prior to cell culture. 
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Figure 13. Reduced F4/80+Gr1int expression in the presence of neutralizing GM-CSF antibody. 
A neutralizing GM-CSF antibody (R&D Systems) was administered on day 1, 3 and 4 of LPS administration (1 
µg/mouse/day).  On day 5, following lung tissue digestion, total lung cells were examined by flow cytometry.  
Results are representative of 2 independent experiments (n = 3-4 per group). 
2.4.6 Generation of MDSC is reduced in the absence of STAT5A signaling in vitro and in 
vivo. 
With the understanding that GM-CSF and LPS are both critical for MDSC development in vitro, 
we investigated the role of STAT5, an intracellular mediator downstream of both LPS and GM-
CSF.  GM-CSF is known to signal via STAT5, and LPS triggers STAT5 activation via the 
induction of GM-CSF196.   Myeloid-lineage cells deficient in STAT5A show reduced 
proliferation in response to GM-CSF197. Therefore we hypothesized that MDSC development 
involves cooperative effects of the GM-CSF/STAT5 and TLR/MyD88/NF-κB pathways. 
To determine the importance of STAT5 for MDSC development, we utilized STAT5A-/- 
mice to investigate the development of both bone marrow-derived MDSCs in vitro and lung 
MDSCs in vivo.  We observed reductions in both BMDC and bone marrow MDSC generation in 
the STAT5A-/- cells (Figure 14a).  Gr1 expression was also increased in STAT5A-/- BMDCs 
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revealing a role for GM-CSF-STAT5 signaling in the balance between granulocyte and 
macrophage differentiation in agreement with previously published reports67,198.  Furthermore, 
CD11b-positive cells purified from STAT5A-/- bone marrow MDSC cultures produced less IL-6 
in the presence of either GM-CSF alone or GM-CSF + LPS over the course of 24 hours (Figure 
14b), highlighting the importance of STAT5A signaling in IL-6 production.  
Lung MDSC accumulation was reduced to ~50% of WT in the absence of STAT5A 
(Figure 15a), which was also accompanied by a reduction in IL-6 production.  Interestingly, a 
statistically significant increase in NO production from STAT5A-/- bone marrow or lung MDSCs 
was not observed(not shown), indicating that the regulation of NO by GM-CSF (Figure 12c) is 
STAT5A independent.  Utilization of STAT5A-/- mice thus uncovered a mechanism by which 
accumulation of LPS-generated lung MDSCs is regulated in vivo.  
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Figure 14. STAT5A deficiency alters BMDC and MDSC generation in vitro with reduced IL-6 
production. 
Bone marrow cells were flushed aseptically from the femurs of WT and STAT5A-/- mice.  The cells were cultured at 
a concentration of 1x106 cells/ml and were supplemented with 10 ng ml-1 of GM-CSF in the absence or presence of 
LPS (Escherichia coli, strain O26:B6). (a) On day 7, GM-CSF alone cultures were harvested and examined for 
phenotypic markers (BMDC). On day 9, GM-CSF+LPS cultures (MDSC) were harvested and cells were examined 
for phenotypic markers.  (b) CD11b purified cells from 9 day GM-CSF + LPS cultures were washed twice and 
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seeded at a concentration of 1x106 cells/mL overnight in the presence of GM-CSF or GM-CSF + LPS.  Cell free 
supernatants were analyzed for IL-6 by ELISA.   Results are representative of at least 2 independent experiments. 
 
 
Figure 15. Gr1int accumulation is reduced in STAT5A-/- mice, and Gr1int cells produce less IL-6 
as compared to WT MDSC-like cells in the lung. 
1 µg LPS was administered to WT and STAT5A-/- mice for 4 consecutive days.  (a) Gr1int accumulation was less in 
the STAT5A-/- mice. (b) STAT5A-/- Gr1int cells were purified and put in culture overnight at 37°C in the presence or 
absence of GM-CSF (10 ng/ml) and LPS (1 µg/ml).  IL-6 was measured in cell free supernatants by ELISA.  Data 
representative of 2 independent experiments (n = 3 mice per group).  Cells from individual mice were pooled for cell 
culture cytokine analysis. 
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2.4.7 IL-6 is an MDSC-survival factor ex vivo. 
As shown in Figures 14 and 15, GM-CSF signaling plays a role in the production of IL-6, and is 
critical for the development of lung MDSCs (Figures 11-15).  LPS-generated lung-MDSCs 
produce IL-6 (Figure 16a).  Furthermore, IL-6 signals via STAT3, a critical mediator of tumor 
MDSC generation1,83.  Therefore, we examined lung MDSC survival ex vivo in the presence of 
neutralizing IL-6 antibody and found that IL-6 is critical for MDSC survival ex vivo (Figure 
16b-c). 
 
Figure 16. Gr1int cells produce IL-6 and neutralization of IL-6 reduces the number of Gr1int cells 
cultured ex vivo. 
 (a) 1 mg of LPS was intratracheally administered every 24 h.  Mice were sacrificed at the indicated time points.  
Gr1int cells were isolated, cultured overnight and cell free supernatants were analyzed by ELISA for IL-6.  (b) 
Antibody mediated neutralization of IL-6 in culture resulted in (c) fewer live Gr1int cells after 24 h culture as 
assessed by trypan blue exclusion. Results representative of 2 independent experiments. 
2.4.8 Interleukin-6 is critical for survival following intratracheal LPS administration. 
These studies revealed that lung-MDSC development is dependent upon LPS, GM-CSF, and 
STAT5A signaling, as well as IL-6 production for their survival.  We went on to utilize IL-6-/- 
animals in an attempt to further understand the importance of IL-6 in the development of lung-
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MDSCs.  Strikingly, IL-6-/- were unable to survive following 2 administrations of LPS (Figure 
17) highlighting the importance of IL-6 in the regulation of a response to lung endotoxin 
exposure. 
 
Figure 17. IL-6 is critical for survival following intratracheal LPS administration. 
WT and IL-6-/- mice were treated with 10 µg LPS/day.  (a) After 2 LPS administrations, all the IL-6-/- succumbed, 
while the WT had 100% survival. (b) Lungs and spleens were harvested from naïve WT and IL-6-/- mice.  Total lung 
or spleen cells were purified and cultured (1x106 cells/ml) for 24 hours at 37°C ± LPS (1 µg/ml).  Cells were 
pelleted and resuspended in TRIZOL Reagent.  mRNA was purified and IL-6 expression was quantified by QRT-
PCR.  Data combined from 2 independent experiments. 
2.4.9 STAT1 is a negative regulator of MDSC-like cell accumulation in the lung. 
Given the relationship between STAT3 and STAT1, we explored STAT1 as a negative regulator 
of lung MDSC development and function.  The findings regarding STAT1 as a negative 
regulator are discussed in greater detail in the context of bacterial pneumonia (Section 3.4.6), but 
in brief, it was found that numbers of lung MDSCs double in STAT1-/- mice, which correlated 
with increased IL-6 and IL-10 in lung homogenates.  These results illustrate the potential for 
therapeutic treatment modalities targeting STAT1 in the context of bacteria pneumonia. 
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2.5 DISCUSSION 
These data highlight the therapeutic potential of MDSCs in the control of atopic disease.  In light 
of the novel finding that addition of LPS to bone marrow cultures induces the generation of a 
suppressive cell type, the majority of our studies focused on LPS as the major player in MDSC 
generation.  However, GM-CSF is recognized as an equally contributing factor, given that 
MDSCs cannot be generated in vitro in its absence.  Additionally, our data indicate that in vivo 
neutralization of GM-CSF during MDSC development results in a deficiency in MDSC-IL-6 
production in comparison to WT MDSC.  Reduced IL-6 production also correlated with reduced 
lung MDSC in the STAT5A-/- as well as reduced survival ex vivo in the presence of neutralizing 
IL-6 antibody.   
Unique to the biology of the lung is the continual inhalation of microbial products and 
exposure to pathogens. Endotoxin exposure in the lung induces rapid neutrophil influx and GM-
CSF production, facilitating recruitment of myeloid cell populations and hematopoietic 
progenitors from the bone marrow.  Although there is not a profound defect in myeloid-cell 
development in GM-CSF-deficient mice, GM-CSF signaling in the lung is crucial for lung 
homeostasis as evidenced by the development of alveolar proteinosis in its absence48.  Of great 
relevance to our studies, GM-CSF has recently been shown to promote bone metastasis of breast 
cancers199 and high doses of GM-CSF alone have been shown to convert human monocytes into 
a regulatory DC phenotype200.  Additionally, a murine trial using a GM-CSF vaccine strategy 
demonstrated rapid tumor progression rather than the intended boost in anti-tumor immunity69.  
GM-CSF and TLR4 signaling are integrally related for their function.  GM-CSF has been shown 
to prevent endotoxin-mediated tolerance by promoting interaction between MyD88 and 
IRAK1201.  It has also been shown to be important for macrophage-derived IL-6 production in 
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response to high concentrations of LPS72.  In addition, GM-CSF is vital for pulmonary immunity 
to LPS, since the amplification of the LPS-induced response requires Akt/Erk activation of 
NFkB and AP-1 by GM-CSF73. Taken together, we hypothesize that GM-CSF plays an integral 
role in the development of LPS-induced lung MDSCs. 
We have demonstrated that lung MDSC-like cells can be expanded in vitro from lineage 
negative progenitor cells in a manner dependent on both LPS and GM-CSF.  Furthermore, LPS 
administration following adoptive transfer of lineage negative progenitors demonstrates the 
potential for a lineage negative progenitor to be the precursor of in vivo MDSC-like cells in the 
lung, complementing studies done by von Andrian and colleagues64. 
Functioning downstream of GM-CSF, STAT5A is an important signaling molecule for 
IL-6 production and both in vitro and in vivo expansion of MDSC-like cells.  Although STAT5 is 
a key transcription factor involved in GM-CSF function, STAT5A-/- mice do not show defects in 
myeloid development.  On the contrary, the transcription factor PU.1 is known to regulate 
lineage differentiation during the earliest stages of macrophage and granulocyte differentiation.  
It belongs to the Ets family of transcription factors, is activated by both TLR and GM-CSF 
signaling, and is essential for myeloid differentiation45,202.  As a determinant of cellular 
differentiation, PU.1 may play a fundamental role in MDSC development from a lineage 
negative progenitor cell in vitro, as well as in vivo.  More relevant, PU.1 over-expression can 
bypass the need for endogenous GM-CSF in lung alveolar macrophages 72.  Indeed, the effects 
that have been observed by blocking GM-CSF in vivo may be mediated through PU.1 in addition 
to STAT5A.  We chose to focus on STAT5 due to its potential role in driving IL-6 production, 
and investigated the contribution of STAT5A in MDSC development and function due to its 
specific association with IL-6 production.  However, STAT5B is also activated downstream of 
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GM-CSF and may be equally important for lung-MDSC generation.  PU.1 gene disruption 
results in severe defects in myeloid differentiation and a conditional knockout would be 
necessary to investigate its role in MDSC development203,204.   
Taken together, these studies reveal the contribution of STAT5 and GM-CSF, in 
combination with LPS, as critical mediators of bone marrow and lung-MDSC generation.  
Administration of GM-CSF in the lung may have application for reduced Th2 inflammation, and 
blockade of STAT5 is a yet unappreciated mechanism by which to control MDSC generation. 
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3.0  A ROLE FOR IL-10 IN EFFEROCYTOSIS OF APOPTOTIC NEUTROPHILS 
AND RESOLUTION OF INFLAMMATION PRODUCED BY STAT1-REGULATED 
LUNG MDSC-LIKE CELLS 
3.1 ABSTRACT 
Bacterial pneumonia remains a significant health care burden worldwide.  Although an 
inflammatory response in the lung is required to fight the causative agent, persistent tissue-
resident neutrophils in non-resolving pneumonia can induce collateral tissue damage and 
precipitate acute lung injury.  However, little is known about mechanisms orchestrated in the 
lung tissue that remove apoptotic neutrophils to restore tissue homeostasis under normal 
circumstances. In mice infected with Klebsiella pneumoniae, a bacterium commonly associated 
with hospital-acquired pneumonia, we show that interleukin-10 is essential for resolution of lung 
inflammation and recovery of mice after infection. Although IL-10-/- mice cleared bacteria, they 
displayed increased morbidity with progressive weight loss and persistent lung inflammation in 
the later phase of the immune response to infection. A source of tissue IL-10 was found to be 
resident CD11b+Gr1intF4/80+ cells resembling myeloid-derived suppressor cells that appeared 
with a delayed kinetics after infection.  These cells efficiently efferocytosed apoptotic 
neutrophils, a process which was aided by IL-10.  The lung neutrophil burden was attenuated in 
infected STAT1-/- mice with concomitant increase in the frequency of the MDSC-like cells and 
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lung IL-10 levels. Thus, inhibiting STAT1 in combination with antibiotics may be a novel 
therapeutic strategy to address inefficient resolution of bacterial pneumonia. 
3.2 INTRODUCTION 
Bacterial infection leading to pneumonia is a leading cause of morbidity and mortality 
worldwide with more than 3 million cases occurring annually in the United States alone and 
resulting in 40,000 to 70,000 deaths each year 205.  Additionally, the majority of deaths during 
the 1918-19 influenza pandemic were actually due to secondary bacterial infections following 
viral clearance 206. Characteristically, defense against pathogenic bacteria involves a set of finely 
tuned orchestrated events whose goal is to rapidly mount an innate immune response to clear the 
pathogen 105,106.  The cells of the innate immune response that are able to phagocytose and kill 
the bacteria once internalized are the alveolar macrophages and neutrophils 105,106.  Typically, 
alveolar macrophages (AMs) participate initially and their numbers dwindle as neutrophils are 
rapidly recruited to the site of infection 207. Neutrophils produce a range of products including 
reactive oxygen species and proteases that are not only harmful for the pathogen but also for the 
host’s own cells 135,205,208-210.  Therefore, once the pathogen is cleared, it is crucial for the host to 
mount an appropriate anti-inflammatory response to limit further neutrophil recruitment and to 
clear the dead cells. However, bystander tissue injury caused by unmitigated inflammation after 
infection can initiate and lead to the progression of acute lung injury (ALI) that can be fatal.  
Indeed, severe pneumonia is a common underlying cause of acute lung injury and its more 
formidable form, acute respiratory distress syndrome (ARDS) 205,211. It is, therefore, important to 
understand the molecular and cellular mechanisms that mediate innate immune system 
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dysfunction so that tissue homeostasis after infection can be rapidly restored with therapeutic 
intervention, if necessary.    
Excess tissue IL-10 levels early after infection inhibits bacterial clearance thereby acting 
as a negative regulator of host defense 105,124,165.  However, IL-10 is also known to be important 
for maintenance of homeostasis as well as regulation of neutrophil clearance (decrease 
survival/efferocytosis) 105,124,126,190,212.  These two observations, while seemingly contradictory, 
point to the need for early absence of IL-10 to facilitate bacterial clearance but with its presence 
being necessary during the resolution phase of the immune response. A central unanswered 
question in the context of bacterial pneumonia is which cell type(s), with the potential to produce 
IL-10 in the lung tissue, like AMs in the alveolar lumen, aid in the removal of apoptotic 
neutrophils (efferocytosis) effecting resolution of inflammation. This question is important 
because neutrophils in the alveolar space represent only a fraction of the extravasated neutrophils 
in the inflamed lung and do not necessarily track with parenchymal neutrophil burden 213,214. In 
contrast, interstitial neutrophils have been found to be more intimately associated with clinically 
relevant measures of ALI, such as increased microvascular permeability and decreased lung 
compliance 135,208,209.  Thus, there appears to be an indispensible role for additional cellular 
players in the alveolar interstitium to limit lung injury by inhibiting the continuous tissue influx 
of neutrophils after infection and to efferocytose apoptotic neutrophils.  
We recently described a CD11b+Gr1intF4/80+ regulatory cell population in the lung that 
expands in response to LPS exposure in a TLR4/MyD88-dependent manner 5.  We showed that 
these cells have the ability to suppress Th2 effector responses via secretion of IL-10.  These cells 
also secrete IL-6 and GM-CSF, but low levels of IL-12.  Due to their close resemblance to 
myeloid-derived suppressor cells (MDSCs), these Gr1int cells are now recognized as lung 
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MDSCs 1.  It is known that mice lacking functional MyD88 signaling have increased 
susceptibility to a number of infectious pathogens, including the Gram negative bacterium 
Klebsiella pneumoniae 112.  K. pneumoniae is a common bacterial species acquired by 
nosocomial infections that can cause pneumonia in severely ill patients with a high rate of 
morbidity and mortality.  In fact, K. pneumoniae was found to be the third most commonly 
isolated organism from intensive care units in the US 101.  In our previous study, we observed IL-
10 production by tissue-resident MDSC-like cells in response to LPS 5. In the present study we 
addressed whether these cells represent a source of IL-10 after infection with K. pneumoniae and 
if so, whether this is beneficial for the host.  This question arose because presence of IL-10 early 
after infection with K. pneumoniae was deleterious and increased bacterial load in the lung.  
However, IL-10 was crucial for resolution of inflammation and eventual recovery of mice late 
after infection. The MDSC-like cells were found to expand in the lungs with delayed kinetics in 
response to bacterial infection and therefore produced IL-10 only in the later phase of infection.  
Functionally, the cells efferocytosed apoptotic neutrophils, which was partially dependent on IL-
10. In our efforts to identify mechanisms that would increase the MDSC:neutrophil ratio which 
presumably would help in the resolution process of neutrophilia, we found that deletion of 
STAT1 caused a doubling of MDSC-like cells with concomitant reduction of tissue neutrophils. 
In the absence of STAT1 signaling, IL-6 and IL-10 levels in the lung increased, both of which 
signal through STAT3, a known mediator of proliferation and survival of MDSC-like cells 1,83. 
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3.3 MATERIALS AND METHODS 
3.3.1 Animals and reagents 
Male 6-8-week old C57BL/6 mice, and IL10-/- mice on C57BL/6 background (stock number 
002251), were purchased from the Jackson Laboratory (Bar Harbor, ME).  STAT1-/- mice 
previously generated 127 were bred at the animal facility at the University of Pittsburgh. All mice 
were housed under pathogen-free conditions and were used between 6 and 10 weeks of age.  
Within experiments, the mice were age and sex matched.  All studies with mice were approved 
by the Animal Care and Use Committee at the University of Pittsburgh.  LPS from Escherichia 
coli, strain O26:B6, was obtained from Sigma.  A number of fluorochrome-confugated 
monoclonal antibodies were used in cell phenotyping experiments as follows: PE-labeled anti-
mouse CD11b, APC-labeled anti-mouse CD11c (clone HL3), APC-labeled anti-mouse Gr1 
(clone RB6-8C5), PE-labeled anti-mouse Ly6G (clone 1A8), Alexa 647-conjugated mouse anti-
STAT3 (pY705, clone 4/P-STAT3), neutralizing anti-mouse IL-6, and neutralizing anti-mouse 
IL-10, all of which were purchased from BD Biosciences.  Alexa 488-, PE- and APC-labeled 
anti-mouse F4/80 were purchased from Caltag Laboratories.  
3.3.2 Infection 
All infections were done with K. pneumoniae ATCC 43816 as described previously 117.  
Bacterial growth medium was seeded with a 1:100 dilution of an overnight culture of K. 
pneumoniae and the culture was incubated for 2 h to attain mid logarithmic phase.  The OD600 of 
the culture was determined (1 OD600 = 5x108 CFU) and the inoculum was diluted accordingly.  
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For infection, the mice were anesthetized with isoflurane and 1x102 or 1x103 CFU were 
delivered by intratracheal instillation215.  The exact CFU was routinely estimated by plating 
dilutions of the inoculum on tryptic soy agar plates.  Lung and systemic burden of K. 
pneumoniae were determined by plating dilutions of homogenized lung tissue or blood in PBS 
on tryptic soy agar plates.  CFU were enumerated following overnight incubation at 37°C. 
3.3.3 Generation and isolation of MDSC-like Gr1int cells from the lung 
MDSC-like cells were induced in the lung and isolated as previously described in 2.3.3. The 
Gr1int were purified in an identical manner 24 or 72 h post infection with K. pneumoniae.  The 
staining procedures to identify CD11b+Gr1intF4/80+ cells were described previously in 2.3.3. 
3.3.4 Histology and quantitation using Metamorph 
Tif images of Hematoxylin & Eosin (H&E) stained lung sections (5 µm) were scanned using a 
Mirax MIDI (Zeiss, Budapest, Hungary) microscope.  Digital images were captured using 
Panoramic Viewer (Version 1.14; 3D Histech) and analyzed using Metamorph.  Following color 
separation, the blue layer was converted to monochrome.  The entire lung was selected as a 
region and the threshold was set to 195 for all images.  Region statistics were calculated.  % 
Threshold area was determined by dividing the threshold area by the total area of the lung 
(region).  Threshold Area/Total Area x 100 = % Threshold Area. 
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3.3.5 Efferocytosis assay 
Neutrophils (PMNs) were purified from the lungs of LPS-treated mice by FACS of the 
Ly6GhiF4/80- population following CD11b purification (Miltenyi Biotec Automacs technology).  
PMNs were cultured overnight at 37°C under serum free condition to induce apoptosis 125. 
Apoptotic PMNs were detected by Annexin V/propidium iodide (PI) staining.  The PMNs were 
labeled with DDAO-SE (Molecular Probes). Gr1int cells were purified by FACS from CD11b+ 
lung cells labeled with Alexa 488-conjugated anti-mouse F4/80 and PE-conjugated anti-mouse 
Gr1.  Apoptotic PMNs and Alexa 488 labeled Gr1int cells were incubated together (10:1 ratio) for 
30 minutes at 37°C.  % uptake was quantified by flow cytometry.  Confocal images were 
captured on an Olympus Fluoview FV1000 confocal microscope using a 60x Objective (NA 
1.35).  Following the efferocytic assay, Gr1int MDSC-like cells labeled with Alexa 488-
conjugated anti-mouse F4/80 and DDAO-SE (Molecular Probes)-labeled PMNs were detected 
using the excitation wavelengths 488 nm and 635 nm, respectively. Z-stack projections were 
created from 0.75-µm optical increments spanning the thickness of the cell. 
3.3.6 Intracellular cytokine staining 
Freshly isolated PMNs, Gr1int and F4/80+ cells were incubated with LPS (1µg/ml) and Brefeldin 
A (10 µg/ml) (Sigma) for 4 h. Cells were harvested, washed twice with PBS-2% fetal bovine 
serum (FBS) and then fixed in 4% paraformaldehyde solution for 15 min at room temperature. 
After washing the cells twice, cells were incubated in permeabilization buffer for 30 min at room 
temperature. Cells were then centrifuged, washed in permeabilization buffer and resuspended in 
APC-labeled anti-mouse IL-10 (BD Biosciences) or APC-labeled Rat IgG2b control antibody for 
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30 min at room temperature. Cells were finally sequentially washed in permeabilization buffer 
and PBS-2% FBS and analyzed by flow cytometry. 
3.3.7 pSTAT3 analysis 
Lung cells were isolated as previously described 5.  Intracellular staining for phsophoSTAT3 
(pY705) was performed according to BD Phosflow protocol for intracellular staining.  Briefly, 
cells were left unstimulated or stimulated with recombinant mouse IL-6 at 100 ng/mL for 15 
minutes at 37°C.  Cells were then fixed using Fix Buffer 1 (Cat#: 557870) for 10 minutes at 
37°C, washed, and stained for CD11b and Gr1 to phenotypically identify the CD11b+Gr1int 
population.  Cells were permeabilized with Perm Buffer III (Cat#: 558050) on ice for 30 
minutes, washed twice, and stained with pYSTAT3 (Cat#: 557815) or isotype control (Mouse 
IgG2ak Cat#: 558052).  Intracellular staining was performed at room temperature for 30 min.   
3.3.8 qRT-PCR 
Quantitative RT-PCR was performed as previously described 146 as follows.  Tissues or cells 
were treated with TRIzol (Invitrogen).  RNA was isolated with the RNeasy kit (Qiagen) and 
treated with RNase-free DNase (Qiagen).  cDNA was synthesized and used for quantitative PCR 
with TaqMan Gene Expression Assays (Applied Biosystems) according to the manufacturer’s 
instructions.  The level of mRNA was normalized to HPRT1 expression, and the results were 
analyzed by the 2-ΔΔCt method.  Fold expression of IL-10 in STAT1-/- Gr1int cells was calculated 
relative to expression of IL-10 in WT Gr1int cells both harvested 72 h post infection with 1000 
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CFU K. pneumoniae.  The level of expression was normalized to that of the housekeeping gene 
HPRT and the results were analyzed using the 2-ΔΔCt method. 
3.3.9 Cytokine analysis by ELISA 
Cytokine production from CD11b+Gr1intF4/80+ cells and CD11c+ alveolar macrophages was 
assessed by culturing the cells (1x106 cells/ml) overnight at 37°C in RPMI 1640 (Gibco) medium 
supplemented with 10% heat-inactivated FBS (Gemini), 100 U/ml of penicillin, 100 mg/ml of 
streptomycin sulfate (Gibco), 1 mM sodium pyruvate (Gibco) and 50 µM 2-mercaptoethanol 
(Sigma). All reagents used had <0.6 U/ml of LPS .  Secreted cytokines were measured by 
multiplex cytokine assay (Bio-Rad Laboratories) or ELISA (murine Duo Set; R&D Systems), 
according to the manufacturers’ instructions. 
3.3.10 Statistical analyses 
Comparisons of means± s.d. were performed using one-way analysis of variance or Student’s t-
test using GraphPad Prism software (La Jolla, CA). Differences between the groups were 
considered significant if p < 0.05. 
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3.4 RESULTS 
3.4.1 Establishment of an LD50 dose of K. pneumoniae 
IL-10 has been negatively associated with the deployment of rapid defense mechanisms against 
bacterial infection 105,124,165.  However, its role in the resolution of tissue inflammation induced to 
clear the pathogen has not been adequately addressed.  Our goal was to determine whether wild-
type (WT) and IL-10-/- mice differentially respond to acute bacterial infection over time. To 
address this goal, we wished to use a dose of the bacterium that would allow ~50% of the wild-
type (WT) mice to recover from infection and observe whether lack of IL-10 would make a 
difference in this recovery. Towards this end, we infected WT mice with two doses of the 
bacterium, 100 and 1000 colony forming units (CFU), to compare the outcome.  Mice infected 
with 100 CFU experienced less weight loss (Figure 18a) and systemic dissemination on day 3 
after infection (Figure 18b) compared with those infected with 1000 CFU. Systemic cytokine 
levels were also lower in mice infected with the lower dose (Figure 18c) and the lungs appeared 
less inflamed (Figure 18d). Histological examination of lung sections of mice infected with 
1000 CFU showed significantly more inflammation at 72 h compared to that observed at earlier 
time points (Figure 18e). At 72 h after infection, all of the mice infected with 100 CFU had 
recovered.   
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Figure 18. Establishment of an LD50 dose of K. pneumoniae infection 
WT C57BL/6 mice were infected intratracheally with either 100 or 1000 CFU K. pneumoniae (ATCC: 43816, 
serotype 2) and various parameters were recorded. (a) % Body weight loss from baseline was recorded at indicated 
time points. (b) Blood colony forming units (CFU) 72 h post infection. (c) Serum cytokine and chemokine levels 24 
h post infection. Data shown are means ± s.d. (d) Representative photographs of lungs showing more injury at the 
higher bacterial dose.  (e) Increased cellular infiltration over time is visible via hematoxylin and eosin (H & E) 
staining of lung sections of mice infected with 1000 CFU of K. pneumoniae.   
 
With the higher dose of 1000 CFU, however, at 72 h after infection, ~ 50% of the WT mice 
displayed continued loss of weight and body temperature, greater systemic dissemination of 
bacteria, (Figure 19a-c) and appeared huddled and withdrawn from food.  These moribund mice 
were placed in one group while the remaining 50% that received the same high bacterial dose, 
but did not appear sick and were active, were labeled survivors and placed in the other group. 
We compared various parameters between these two groups of mice all sacrificed on day 3 post-
infection.  The level of IL-10 was significantly higher in the lungs of the mice with more sever 
disease, and correspondingly, the percentage of polymorphonuclear neutrophils (PMNs), 
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required for rapid bacterial clearance, was lower in the lungs of this group (Figure 19, d-e).  
Thus a dose of 1000 CFU was chosen to examine whether presence or absence of IL-10 made 
any difference to the recovery of mice after bacterial infection.  All of the subsequent 
experiments were performed using the LD50 dose of 1000 CFU to address the importance of IL-
10 in resolution of lung inflammation and recovery after bacterial infection.  
 
Figure 19. Survivors display better parameters of health compared to moribund mice, both 
infected with 1000 CFU of bacteria. 
At 72 h post infection with 1000 CFU K. pneumonia, 50% of the sick/moribund mice showed (a) increased weight 
loss and (b) decreased body temperature.  (c) Increased bacterial dissemination, as measured by estimation of log 
CFU/mL in blood, was also observed in mice displaying increased morbidity, which correlated with (d) increased 
lung IL-10 and (e) decreased PMN in BAL.  Data shown are representative of 3 independent experiments with 
n=10-12 mice/group. 
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3.4.2 Early Versus Late Interleukin-10 during infection By Klebsiella pneumoniae  
To assess the role of IL-10 in defense against K. pneumoniae, WT and IL-10-/- mice were 
infected with 1000 CFU of the bacterium.  We compared the outcome in the two groups with 
respect to inflammation, bacterial burden in the lung, systemic bacterial load and weight loss. 
Early after infection at 48 h, the IL-10-/- mice showed limited lung pathology and carried lower 
bacterial burden in the lung compared to the WT mice (Figure 20a). These results were in line 
with previous observations of delayed mortality and reduced bacterial burden in the lungs of 
mice in which IL-10 was neutralized prior to infection with a dose of K. pneumoniae that was 
lethal for the strain of mouse used (CD-1)165.  The difference between the prior study and ours is 
that we used a LD50 dose, where 50% of mice repeatedly succumbed post infection, to study 
effects of complete IL-10 deficiency on lung health and bacterial dissemination late after 
infection.  The rationale for our experimental design was that while lack of IL-10 initially might 
help in bacterial clearance, it is unknown how its absence would impact resolution of lung 
inflammation and recovery after infection.  
 75 
 
Figure 20. IL-10 deficiency worsens outcome late after infection. 
To determine the role of IL-10 early versus late after infection, WT and IL-10-/- were infected with 1000 CFU of K. 
pneumoniae. (a) 48 h post infection mice were sacrificed.  Cellular infiltration was determined by H&E staining of 
lung sections and inflammation in whole lung was quantified using Metamorph, as indicated by % Threshold Area.  
The bacterial burden in the lung was estimated by log CFU/lung.  (b) To examine the role of IL-10 late after 
infection, WT and IL-10-/- mice were infected with 1000 CFU.  50% of WT mice and 20% of IL-10-/- mice were 
sacrificed prior to 144 h on the basis of continued weight loss, drop in body temperature and appearance (data not 
shown).  The mice that did not show signs of morbidity were monitored until day 6 (144 h).  (b) At 144 h post-
infection, WT and IL-10-/- were examined for cellular infiltration by H&E staining and quantified by % Threshold 
Area.  Bacterial dissemination was measured as log CFU/mL blood.  (c) Surviving WT mice recovered from the 
initial weight loss unlike IL-10-/- mice.  Data shown are means ± s.d.  **p< 0.01.  (d) MPO activity was measured in 
the BAL fluid 144 h post infection and total lung homogenates were analyzed for IL-17A, TNF-α, and KC levels 
(n=5-6 mice per group). Data shown are representative of 2 independent experiments. 
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The 50% of WT mice that appeared close to death on day 3 after infection by virtue of 
huddled appearance, withdrawal from food and loss of body weight and temperature were 
euthanized. In contrast, fewer (~20%) of the IL-10-/- mice looked moribund at this time point.  
By 144 h, while the remaining 50% WT mice looked active and on the road to recovery, all of 
the IL-10-/- mice met criteria for euthanasia, which included continued loss of body weight, 
withdrawal from food, loss of body weight and temperature and needed to be sacrificed along 
with the WT survivors (which were active and appeared to have recovered) to assess various 
outcome measures. Analysis of lung histology using Metamorph software showed that compared 
to the lungs of WT mice, those of IL-10-/- mice at 144 h post-infection harbored significantly 
greater inflammation (Figure 20b).  However, we did not observe increased bacterial 
dissemination in the IL-10-/- mice at 144 h (Figure 20b).  Strikingly, using weight loss as a 
global measure of health decline, we observed that the IL-10-/- mice continued to lose weight 
after infection whereas the WT survivors began to regain the weight lost during the initial phase 
of infection with the two groups beginning to diverge at 72 h after infection (Figure 20c).  
Myeloperoxidase 123 activity (a measure of PMN infiltration) was also increased in the IL-10-/- 
mice 144 h post infection (Figure 20d).  Upon further investigation of what criteria 
distinguished the WT from their IL-10-/- counterparts at 72 h, a time point at which the surviving 
WT and the IL-10-/- mice began to diverge with respect to weight loss, we found that the MPO 
activity and the PMN:Mac ratio in the BAL fluid was greater in the IL-10-/- mice as compared to 
that in the WT mice (Figure 21, a-b).  However, the majority of the IL-10-/- mice had 2 logs 
lower CFU in their blood at this time point compared to the WT mice (Figure 21c). Thus, in our 
analysis, the key difference at 72 h that was disadvantageous to the IL-10-/- mice was more 
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inflammation in the lungs as compared to that in the WT counterparts.  No systemic bacteria 
were detected in the surviving WT mice after 8 days of infection (Figure 21d).   
 
Figure 21. Improved bacterial clearance and increased PMN recruitment in IL-10-/- mice. 
WT and IL-10-/- mice were infected with 1000 CFU of K. pneumoniae. At 72 h post-infection, (a) MPO activity was 
measured in cell free BAL fluid, and (b) PMN and Macrophage (Mac) numbers in BAL cells were assessed 
(expressed as a ratio). (c) Bacterial dissemination was lower in IL-10-/-. (d) Clearance of systemic bacteria is 
achieved in surviving WT mice by day 8 after infection with 1000 CFU.  Data shown are representative of 2 
independent experiments (n=6-8 mice per group).  
. 
We examined the levels of two cytokines, IL-17A and TNF-α, and the neutrophil 
chemoattractant KC in the lungs of the mice 144 h after infection, the combination of which was 
found to promote lung neutrophilia in response to fungal infection in our recent study146.  As 
shown in Figure 20d, the levels of all of these molecules were significantly higher in the lungs 
of the IL-10-deficient mice at 144 h after infection, which might explain the increased PMN 
burden in these mice late after infection (Figure 20 and Figure 21). qRT-PCR analysis of 
steady-state RNA levels at 144 h for the most part also matched the protein data (Figure 22). 
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The lack of correspondence between RNA and protein for TNF-α may be due to 
posttranscriptional regulation of protein expression 216.  Taken together, these results suggested 
that the increased morbidity observed in the IL-10-/- mice over time was not due to failure to 
clear bacteria but that the mice continued to harbor an overwhelming inflammatory response in 
the lungs in the absence of IL-10, which was already evident at 72 h after infection.  
 
Figure 22. Increased expression of cytokines and chemokines associated with neutrophil 
recruitment in IL-10-/- mice. 
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WT and IL-10-/- mice were infected with 1000 CFU of K. pneumoniae.  Lung mRNA was analyzed for expression of 
cytokines and chemokines by qRT-PCR techniques 48 and 144 h post infection.  Data shown are representative of 2 
independent experiments (n=5-6 mice per group).  
 
3.4.3 Gr1int MDSC-like cells expand in response to K. pneumoniae and produce IL-10. 
Alveolar macrophages (AMs) are known to participate in the removal of cellular debris 
following infection.  However, because they are confined to the alveolar lumen, there is a 
requirement for additional cellular players to remove apoptotic neutrophils in the lung 
interstitium in order to restore tissue homeostasis.  Our previous work identified a myeloid cell 
with the phenotype CD11b+Gr1intF4/80+ resembling myeloid-derived suppressor cells (MDSCs) 
whose numbers increase in the lung tissue in response to LPS in a dose-dependent fashion and 
which produce IL-105. As described previously5, the cells are largely Ly6Gint/Ly6Clo/- and 
resemble granulocytic MDSCs.  These cells constitute >60% of F4/80+ cells in the lung at 72 h 
after LPS instillation or bacterial infection.  Given the anatomical location of these lung MDSC-
like cells as well as their ability to proliferate in response to LPS, we examined the kinetics of 
their expansion and IL-10-producing ability in response to K. pneumoniae.  As shown in Figure 
23, the number of the Gr1int MDSC-like cells (labeled as Gr1int cells) did not change at 24 h after 
infection but increased significantly at 72 h after infection.  Since AMs are also known to 
produce IL-10, we next simultaneously investigated the expansion of both AMs and the Gr1int  
cells after infection with 1000 CFU of K. pneumoniae. More AMs than Gr1int cells were 
recovered from the lungs of naïve mice. At 72 h after bacterial infection, however, the profile 
was reversed with fewer AMs than MDSC-like cells present in the lungs of the infected mice 
(Figure 23a). Typically, AMs participate very early after infection and their numbers dwindle as 
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neutrophils are rapidly recruited to the site of infection 207, which was observed by us as well 
(Figure 24). However, although the AMs reappear over time to be able to clear dying 
neutrophils in the alveolar lumen, at 72 h post-infection, the MDSC-like cells were clearly more 
abundant compared to AMs (Figure 23a). These data suggest a carefully orchestrated 
mechanism the host has evolved to simultaneously allow for an appropriate inflammatory 
response to bacterial challenge with subsequent expansion of MDSC-like Gr1int cells 72 h post 
infection, to temper inflammation and prevent tissue damage.  Importantly, although both AMs 
and lung Gr1int cells were able to secrete IL-10, the total contribution of IL-10 from the 
interstitial Gr1int cells outweighed the amount of IL-10 from the AMs in the lumen late after 
infection (Figure 23b).  We examined IL-10 production from tissue PMNs, Gr1int and total 
F4/80+ cells isolated from the lungs of mice at 72 h after infection with 100 versus 1000 CFU of 
bacteria by intracellular staining techniques.  As shown in Figure 23c, the frequency of IL-10-
secreting cells was highest in the Gr1int population with 100 CFU of infection.  The frequency of 
IL-10-secreting Gr1int cells appeared to diminish with the higher bacterial dose.  The results of 
these experiments showed that with the passage of time after infection when bacteria and PMNs 
infiltrate the tissue, the Gr1int cells expand as IL-10-producing cells in the lung. They appear with 
a delayed kinetics so as not to produce IL-10 too early to impede PMN recruitment for bacterial 
clearance.  
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Figure 23. Gr1int MDSC-like cells are the IL-10 producers in the lung interstitium 72 h post 
infection. 
(a) Gr1int cell numbers were assessed at indicated times after infection of mice with 1000 CFU of K. pneumoniae.  
AMs and Gr1int cells were quantified by flow cytometric analysis in naïve mice as well as in mice at 72 h post 
infection (PI). AMs were identified by flow cytometry based on CD11c expression and high autofluorescence while 
Gr1int cells were CD11b+Gr1intF4/80+.  Morphology of each cell type is also shown.  (b) At 72 h post infection, Gr1int 
were purified as previously described 5.  AMs were purified by high volume lavage and CD11c magnetic 
purification.  Cells were seeded in equal numbers and after 24 h, cell-free supernatants were analyzed by ELISA for 
IL-10 levels.  Total IL-10 was determined by multiplying the amount of IL-10 produced per cell by the number of 
cells present in the lung 72 h post-infection.  (c) IL-10 secretion was greater from purified Gr1int on a per cell basis 
than total F4/80+ cells isolated 72 h post infection with 1000 CFU K. pneumoniae. (d) Intracellular cytokine 
staining for IL-10 was performed on neutrophils (PMNs), Gr1int, and total F4/80+ cells isolated 72 h post infection 
with 100 or 1000 CFU K. pneumoniae.  CD11b+ cells were purified by AutoMACS technology.  Within the CD11b+ 
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cells, PMNs were CD11b+Ly6GhiF4/80-, Gr1int cells were CD11b+Gr1intF4/80+, and total F4/80+ were 
CD11b+F4/80+.  Data shown are means ± s.d. and are representative of 2 independent experiments.  For cellular 
quantification mice were kept individually (n = 4-5 mice per group).  For cell purification and sorting to determine 
cytokine production (n = 3-4 mice pooled per group). 
 
 
Figure 24. AMs decrease over time post infection. 
High autofluorescent cells were gated and CD11c expression was examined.  AMs were identified based on high 
autofluorescence and high CD11c expression. Data shown are representative of 2 independent experiments. 
3.4.4 Gr1int MDSC-like cells are outnumbered by neutrophils at high bacterial dose. 
While our studies and previous literature collectively show that the host deploys its 
armamentarium of cells in a highly regulated fashion to combat infection, the delicate balancing 
act of mounting inflammation to eliminate the pathogen and then later curbing it to restore 
homeostasis is not always successful.  In patients who fail to recover from bacterial pneumonia, 
overwhelming tissue inflammation precipitates ALI 135,205,208-210.  Since a dose of 100 CFU of 
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bacteria led to complete recovery of all mice while 1000 CFU caused 50% mortality in our 
study, we examined the PMN:Gr1int ratio in the lungs of the mice in response to these doses 24 
and 72 h after infection. Our analysis showed that the numbers of Gr1int cells do not keep up with 
those of infiltrating neutrophils at a higher bacterial burden (Figure 25a,c). In particular, in 
moribund mice infected with 1000 CFU of bacteria, the ratio of PMN:Gr1int cells was ~20, 
compared to a ratio of ~7 in mice with less weight loss (survivors) (Figure 25b) and 2-4 in mice 
infected with 100 CFU (Figure 25c).   
 
Figure 25. Increased PMN infiltration in the lung at higher bacterial burden resulting in an 
increased PMN:Gr1int ratio. 
 (a) The CD11b+ population in the lung was analyzed for Ly6G or Gr1 and F4/80 expression.  Ly6GhiF4/80- cells 
represent PMNs whereas Gr1intF4/80+ cells are the Gr1int lung-MDSC like cells. 1000 CFU of bacteria induced more 
PMN infiltration than 100 CFU at both 24 and 72 h post infection.  (b) Mice infected with 1000 CFU can be divided 
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into 2 groups on the basis of weight loss 72 h post infection.  Therefore, panel (a) also depicts representative flow 
plot of a moribund versus a surviving mouse.  (c) A significantly higher PMN to Gr1int ratio in the lung tissue with 
1000 CFU as compared to 100 CFU of K. pneumoniae.  Total cell numbers (in millions) 72 h post infection were 
PMN: 5.03 +/-1.54; Gr1int: 1.03 +/-0.37 (with 100 CFU) and PMN:15.3 +/-4.3; Gr1int: 0.94 +/-0.36 (with 1000 
CFU). Data shown are means ± s.d. and are representative of 2 independent experiments.  For cellular quantification 
and determination of ratios, mice were kept individually (n = 4-5 mice per group).   
 
3.4.5 Lung MDSC-like cells have the ability to efferocytose apoptotic neutrophils. 
Our next question in the study was whether IL-10-secreting Gr1int cells- cells, appearing with a 
delayed kinetics in the tissue, have the functional ability to remove dying PMNs.  The term 
“efferocytosis” describes the phagocytosis of apoptotic cells, a process shown to promote as well 
as require IL-10 124-126.  Although AMs are known to participate in PMN clearance in the lumen, 
which cell types mediate a similar process in the interstitium is poorly understood.  In order to 
investigate whether the IL-10-producing lung Gr1int cells have efferocytic potential, we labeled 
both apoptotic PMNs and lung Gr1int cells.  The labeled cells were incubated together in culture 
medium and uptake of the fluorescently labeled PMNs by the Gr1int cells was examined. Flow 
cytometric analysis suggested that the Gr1int cells had the ability to efferocytose apoptotic PMNs 
(Figure 26a), which was further substantiated by confocal imaging methods (Figure 26c).  Z-
stack projections confirmed that the neutrophils were contained within the Gr1int cells (not 
shown).  Prior to the efferocytosis assay, PMNs were confirmed to be apoptotic by Annexin V/PI 
flow cytometric analysis and were hypersegmented in morphology (characteristic of apoptotic 
neutrophils) as compared to freshly isolated PMNs (Figure 26b).  Furthermore, neutralization of 
IL-10 by neutralizing antibody in the efferocytosis assay dose-dependently reduced the 
efferocytic efficiency of the Gr1int cells (Figure 26d).  Thus, IL-10-producing lung Gr1int  cells 
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show the capacity to ingest apoptotic neutrophils and IL-10 enhances the efferocytic potential of 
these Gr1int  cells. 
 
Figure 26. Gr1int cells efferocytose apoptotic PMNs. 
 (a) PMNs were purified from the lungs of LPS treated mice (10 µg/day for 3 days) and plated overnight under 
serum free conditions (2x106 cells/mL) to induce apoptosis.  Gr1int cells were purified from the lungs of LPS-treated 
mice as F4/80+Gr1int cells by FACS of Alexa-488- and PE-labeled CD11b+ cells. PMNs were labeled with DDAO-
SE (Molecular Probes). Gr1int and PMNs were cultured together in a 1:10 ratio for 30 min at 370C.  The cells were 
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washed twice and percent uptake was determined by flow cytometry. (b) 35% of the live PMNs (based on forward 
and side scatter) were annnexin V+/PI-.  Morphology is also shown. (c) Confocal images of apoptotic PMNs (red) 
inside of Gr1int (green) cells.  Z-stack projections were taken to confirm intracellular location (not shown).  (d) 
Antibody-mediated neutralization of IL-10 in culture during efferocytosis assay reduced uptake of PMNs by Gr1int 
cells.  Data shown are representative of 2 independent experiments.  For cell purification and sorting of lung-
MDSCs and PMNs, 3-4 mice were treated and total lung cells were pooled for subsequent purification. 
3.4.6 Regulation of Gr1int:PMN ratio by STAT1  
Our data showing efferocytic potential of the Gr1int cells (Figure 26) and blunting of their 
numbers compared to PMNs with high bacterial burden (Figure 25) led us to then ask what 
mechanisms limit Gr1int cellular expansion in the interstitium since if their numbers could be 
expanded, their regulatory properties could be better harnessed to limit immune-mediated 
pathology. 
Tumor-associated MDSCs have been shown to be dependent on STAT3 for both 
expansion and soluble mediator production 1.  In fact, a recent publication highlights the 
importance of STAT3 signaling downstream of Hsp72/TLR2 via autocrine IL-6 production to 
illicit MDSC suppressive function 84.  In our experiments, neutralization of IL-6 blunted Gr1int 
numbers in ex vivo cultures of the cells (See Figure 14).    
STAT1 and STAT3 are known to counterbalance each other with effects on both 
cytokine production and cellular plasticity 1,83,90,91,96.  Given our interest in expanding the Gr1int 
MDSC-like cell type in the lung thereby theoretically enhancing clearance of apoptotic PMNs, 
we asked whether deletion of STAT1 signaling would help promote Gr1int cells and lower PMNs 
in defense against K. pneumoniae.  Towards this end, WT and STAT1-/- mice were infected with 
1000 CFU of bacteria.  At 72 h post infection, the STAT1-/- mice survived and histological 
examination revealed less inflammatory cell infiltration into the lungs compared to the WT mice 
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(Figure 27a).  Not surprisingly, since STAT1 is downstream of type I and II IFNs and controls 
activation of phagocytic cells for pathogen killing217, bacterial dissemination was higher in the 
STAT1-deficient mice (Figure 28a).  However, it is possible that the mice did not immediately 
succumb to infection because STAT1 deficiency was somewhat compensated by adequate levels 
of TNF-α (Figure 28b), which is also important for phagocyte activation218.  Using weight loss 
as an overall measure of health, there was no significantly difference between WT and STAT1-/- 
(Figure 28c) suggesting that, most importantly, the reduced lung histopathology may have also 
sustained the mice.  With regard to effects on the myeloid cells, the STAT1-/- mice showed 
almost a doubling in the numbers of Gr1int cells in the lung with significant reduction in PMN 
numbers as compared to the WT mice (Figure 27b).  Representative flow cytometry data along 
with cell quantifications are shown in Figure 29a-b.  As a side note, we also observed a 
doubling of Gr1int cells in LPS treated STAT1-/- mice (Figure 29c).  The lower numbers of 
PMNs in the STAT1-/- mice also correlated with reduced MPO activity in the BAL fluid (Figure 
27c). The tissue IL-10 level as well as IL-10 gene expression in the Gr1int cells was greater in the 
STAT1-/- mice (Figure 27d-e). The efferocytic potential of the STAT1-deficient Gr1int cells was 
found to be largely intact (Figure 27f).  This is important since STAT1 controls the expression 
of selected molecules involved in phagocytosis219. Since the IL-6/STAT3 axis promotes 
proliferation of MDSCs, we were curious to determine whether the IL-6 level in the lungs of the 
STAT1-/- mice was increased as compared to that in WT mice which was found to be true 
(Figure 27g). Because the level of IL-6 was higher in the lungs of STAT1-/- mice, we asked 
whether STAT3 signaling was enhanced in Gr1int cells isolated from these mice.  In these 
experiments, LPS was used as a surrogate for K. pneumoniae since treatment of STAT1-/- mice 
with LPS also resulted in increased frequency of the MDSC-like cells (not shown). As shown in 
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Figure 27h, IL-6 efficiently induced STAT3 phosphorylation in MDSC-like cells harvested from 
naïve WT (shown) or STAT1-/- mice.  When cells were isolated from LPS-treated WT and 
STAT1-/- mice, higher pSTAT3 levels were detected in response to IL-6 in the STAT1-deficient 
Gr1int cells (Figure 30a). Representative flow cytometry is shown in Figure 30b.  Thus, the 
increased IL-6 levels in the lungs of STAT1-/- mice (Figure 27g) combined with the enhanced 
ability of STAT1-deficient Gr1int cells to respond to IL-6 in the context of inflammation (Figure 
30) may contribute to the increased frequency of the Gr1int cells under STAT1-deficient 
conditions (Figures 27b and 29). 
 
Figure 27. STAT1-/- mice show reduced cellular infiltration upon gross examination with 
decreased frequency of PMNs and increased frequency of Gr1int cells in the lungs following 
1000 CFU K. pneunoniae infection. 
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 (a) WT and STAT1-/- were infected with 1000 CFU.  72 h post infection lungs were examined for histopathology by 
H&E staining and the stained lung sections were quantified using Metamorph. (b) The numbers of Gr1int cells 
increases and PMNs decrease in STAT1-/- as compared to WT 72 h post infection with 1000 CFU of K. pneumoniae.  
(c) STAT1-/- mice showed reduced MPO activity in the BAL fluid compared to that observed in WT mice.  (d) Lung 
IL-10 levels were increased in STAT1-/- mice as compared to that in WT mice. (e) Increased IL-10 mRNA levels in 
STAT1-deficient Gr1int cells as determined by qRT-PCR analysis  (n=3-4 mice/group).  (f) STAT1-/- Gr1int cells can 
efferocytose apoptotic PMNs similar to WT Gr1int cells.  (g) Lung IL-6 levels were increased in STAT1-/- mice as 
compared to that in WT mice.  Data shown are means ± s.d. (n=3 mice/group) and are representative of two 
independent experiments. 
 
 
Figure 28. STAT1-/- mice show increased systemic CFU 72 hours post infection. 
 (a) WT and STAT1-/- mice were infected with 1000 CFU of K. pneumoniae. Blood CFU was determined 72 hours 
post infection and (b) TNF-α was measured in lung homogenates by multiplex. (c) Weight loss was not statistically 
different between WT and STAT1-/- mice.  Data shown are means ± s.d. and are representative of 2 independent 
experiments.  For cellular quantification and determination of ratios, mice were kept individually (n = 4-5 mice per 
group).   
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Figure 29. STAT1-/- have increased Gr1int following infection with 1000 CFU K. pneumoniae or 
LPS administration. 
WT and STAT1-/- were infected with 1000 CFU K. pneumoniae.  (a) CD11b purified cells were stained with anti-
Gr1 and F4/80 and analyzed by flow cytometry.  (b) The numbers of Gr1int cells increases and PMNs decrease in 
STAT1-/- as compared to WT 72 h post infection with 1000 CFU of K. pneumoniae. (c) Increased Gr1int is also 
observed in mice treated with LPS (10ug/day for 3 consecutive days).  Data shown are means ± s.d. and are 
representative of 2 independent experiments.  For cellular quantification and determination of ratios, mice were kept 
individually (n = 3-4 mice per group).   
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Figure 30. STAT1-/- Gr1int have increased pSTAT3 in response to IL-6 treatment. 
(a) The level of Gr1int pSTAT3 expression was analyzed in naïve mice or mice treated with LPS (10 µg/day for 3 
days).  Analysis of pSTAT3 levels in WT and STAT-1-deficient MDSC-like cells ± IL-6 (100 ng/ml) reveals that 
pSTAT3 level is increased in STAT1-/- Gr1int compared to WT. (b) Representative flow cytometry plots are shown.  
The level of pSTAT3 expression expressed as ΔMFI represents the difference in mean channel fluorescence 
intensity of positive staining cells and of those stained with isotype controls. Data shown are means ± s.d. (n=3 
mice/group) and are representative of two independent experiments. 
3.5 DISCUSSION 
Previously shown to be a modulator of allergic inflammation 5, our data now demonstrate a role 
for an MDSC-like cell population in the lung as an innate regulator of inflammation in a model 
of acute bacterial pneumonia.  The delicate balance required between appropriate inflammation 
to clear pathogens in infected tissue and the mitigation of associated immune-mediated 
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pathology to minimize collateral tissue damage is well appreciated in the literature but not 
adequately studied 105. We show that although early IL-10 production hampers bacterial 
clearance from the lung, its complete absence prevents resolution of neutrophilic inflammation 
and recovery of mice.  In the lung, accumulation of interstitial neutrophils during non-resolving 
pneumonia has been associated with the hallmarks of acute lung injury 135,208,209.  However, no 
study to date has described which cells participate in the normal resolution of inflammation after 
bacterial infection so that the process can be improved when the potential for complete recovery 
is in jeopardy. We show that the host expands Gr1int MDSC-like cell numbers in the tissue in 
response to bacterial infection with a delayed kinetics.  These MDSC-like Gr1int cells produce 
IL-10 and can efferocytose apoptotic neutrophils.  Interestingly, efferocytosis by MDSC-like 
cells is aided by IL-10, inviting speculation regarding autocrine/paracrine enhancement of 
efferocytosis during the resolution phase of inflammation. We show that deletion of STAT1 
lowers the neutrophilic burden in the lung with concomitant increase in the proportion of MDSC-
like cells without causing undue morbidity or mortality of the mice. This is important since a 
combination of a STAT1 inhibitor and appropriate antibiotic therapy may help address non-
resolving pneumonia and thereby decrease associated mortality.  
An important initial goal in this study was to determine a dose of K. pneumoniae that 
would cause ~50% lethality early in WT mice but would be less lethal to IL-10-/- mice.  This is 
because from the existing literature, it was clear that early production of IL-10 inhibits neutrophil 
recruitment 105,124,165, neutrophils being important in defense against this bacterium.  We 
therefore expected that we would be able to arrive at a dose that at an early time point would 
impart a survival benefit to the IL-10-/- mice as compared to the WT mice. We reproducibly 
observed a 100% survival rate in WT mice when a 100 CFU of this bacterium was used but only 
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50% survival when a log higher dose was used.  100 CFU induced minor cellular infiltration and 
very minimal lung tissue injury in all WT or IL-10-/- animals (data not shown). Thus a low dose 
would not have allowed us to address our main question, which was the role of IL-10 in host 
defense against K. pneumoniae late after infection, this question being pertinent in resolving 
versus non-resolving pneumonia.  Using the 1000 CFU dose, although the IL-10-/- mice fared 
better initially, they were near death by 144h (6 days) and had to be sacrificed.  Along with the 
dying IL-10-/- mice we also sacrificed the surviving WT mice in order to identify parameters that 
were different between the WT and the IL-10-/- mice 144 h post infection (Fig. 1, Supp Figs S1-
S3).   With a lower dose of 100 CFU, there would not have been enough early immune activation 
to trigger continued neutrophil influx, which contributed to mortality in the IL-10-/- mice at the 
144h time point.  Collectively, while inclusion of data from mice that needed to be sacrificed 
early could have influenced the results presented, we feel that our analysis of mice that survived 
up to 144h has not biased our data addressing differences between IL-10-sufficient and IL-10-
deprived state late after infection.  Since K. pneumoniae is an extremely virulent bacterium for 
many strains of mice, the LD50 is quite low.  For reproducibility, we infected mice with 1000 
CFU each time, which ensured a difference in the outcome between WT and IL-10-/- mice. 
IL-10 can have opposite effects depending on context and timing. For example, during 
murine pneumonia induced by a lethal dose of K. pneumoniae, instillation of anti-IL-10 
neutralizing antibody prior to infection improved bacterial clearance 165. A similar observation 
was made when early production of anti-inflammatory mediators including IL-10 was shown to 
be deleterious to recruitment of neutrophils for defense against Streptococcus pneumoniae 220. In 
each of these studies, anti-IL-10 neutralizing antibody was administered immediately before 
infection and lethal doses of bacteria were used. In contrast, complete absence of IL-10 has been 
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shown to increase tissue injury in multiple infection models involving protozoa, bacteria, and 
nematodes 169 a phenomenon that was similarly evident in our model of bacterial pneumonia in 
which an LD50 dose of K. pneumoniae was used. In our previous study, we showed that the 
expansion of the Gr1int cells in response to LPS is greatly blunted in MyD88-deficient mice 
suggesting dependence on this adaptor protein for their accumulation 5.  Additionally, using GFP 
to track cells in vivo, we showed that a lineage negative bone marrow progenitor population 
when introduced intravenously into mice has the ability to differentiate into MDSC-like cells in 
the lung after intratracheal delivery of LPS 5.  This finding was in agreement with a report 
showing the ability of hematopoietic stem and progenitor cells (HSPCs) in extramedullary 
tissues including the lung to differentiate into CD11c+Gr1+ cells in the presence of LPS 64. It was 
speculated that the purpose of LPS-induced differentiation of HSPCs into myeloid cells was to 
boost immune surveillance although this idea was not experimentally interrogated.  Taken 
together, it seems likely that resident HSPCs differentiate into IL-10-producing Gr1int MDSC-
like cells with a delayed kinetics in response to pathogen-derived signals.   
The molecular regulation of IL-10 in the lung MDSC-like cells has yet to be determined.  
However, data generated through the use of STAT1-/- mice are suggestive of mechanisms 
underlying IL-10 production by these cells.  Given the increased levels of IL-6-induced pSTAT3 
in the STAT1-deficient Gr1int cells, and with IL-6 being a key cytokine produced by these cells, 
a likely positive regulator of IL-10 in the Gr1int cells is STAT3171,179. Reciprocally, as previously 
observed97,174, STAT1 may negatively regulate IL-10 in the Gr1int cells since a significantly 
higher level of IL-10 was detected in the lungs of STAT1-deficient mice along with higher levels 
of IL-10 mRNA in STAT1-deficient MDSC-like cells which may be mediated by increased 
levels of pSTAT3171,179.   
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We observed significantly higher levels of KC expression late after infection in the lungs 
of IL-10-/- mice as compared to that in WT mice.  KC is a known neutrophil chemoattractant 
during acute pulmonary inflammation221.  Furthermore, IL-10 is known to inhibit LPS induced 
KC-mRNA stability 187 suggesting that lack of IL-10 is a primary mechanism contributing to 
increased KC in the IL-10-/- mice which is not advantageous to the host during the resolution 
phase.  Although our primary focus was on regulation of MDSC-like cellular expansion, we also 
observed a decrease in RANTES production in the absence of STAT1 signaling during K. 
pneumonia infection (not shown).  Indeed, RANTES has been linked to neutrophil accumulation 
in the lungs and is also known to be negatively regulated by IL-10, further substantiating our 
finding of a lower neutrophilic burden in the STAT1-/- mice186,222.  Together with expansion of 
MDSCs in the STAT1-/-, the observed reduction in RANTES expression and implicated 
reduction in RANTES-induced neutrophil accumulation further warrants the use of STAT1 
inhibition in the lungs post bacteria infection. 
STAT1 is important for antibacterial host defense as was shown for clearance of Listeria 
monocytogenes from livers and spleens of infected mice129.  STAT1 expression in MDSCs was 
shown to promote Arg1 and NOS2 expression and to be important for the suppressive effects of 
MDSCs on T cells223.  Our previous study also demonstrated the importance of Arg1 and IL-10 
expression in the lung MDSC-like cells for inhibition of Th2 effector function 5.  However, since 
to date Arg1 has not been shown to promote anti-bacterial defense and on the contrary increased 
Arg1 in macrophages compromises bacterial clearance 224, enhancement of IL-10 and decrease in 
Arg1 expression via inhibition of STAT1 in combination with antibiotics may be an ideal 
therapeutic modality for non-resolving pneumonia.  
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In summary, in a model of bacterial pneumonia, we have elucidated a requirement for IL-
10 in resolution of lung inflammation.  We show that Gr1int MDSC-like cells within the tissue 
compartment are a cellular source of IL-10 and that this cell type expands late after infection and 
aids in efferocytosis of apoptotic neutrophils.  MDSCs, including the lung Gr1int cells, harbor 
characteristics of both macrophage/monocytes and neutrophils, and therefore it has not yet been 
possible to selectively deplete these cells by molecular targeting, which would be beneficial in 
the case of tumor-associated MDSCs.  However, given that a desirable goal in non-resolving 
pneumonia is to augment rather than delete this cell type, we postulate that STAT1 may be a 
suitable target to elicit that effect with a concomitant decrease in lung neutrophil burden.  Our 
study further emphasizes the continued need for improved understanding of organ and cell-
specific regulation of IL-10 for the purposes of immune regulation and therapeutic intervention. 
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4.0  CONCLUSIONS 
Following up on the initial recognition of the presence of lung CD11b+Gr1intF4/80+ MDSC-like 
lung cells in response to LPS, the current studies now reveal a role for GM-CSF/STAT5A 
signaling in combination with LPS for the generation of MDSCs.  Furthermore, this work has 
identified lung MDSCs as interstitial cells, which produce IL-10 in response to K. pneumoniae, 
and participate in resolution of inflammation following bacterial pneumonia.   
In our attempts to elucidate mechanisms by which the lung returns to homeostasis 
following bacterial infection we have detailed the coordinated expansion of these cells in the 
lung tissue.  Lung MDSCs exist in very small numbers during the initial phase of host defense 
followed by expansion over the course of 72 hours, well beyond the time when PMNs were 
initially recruited to participate in bacterial clearance.  Although alveolar macrophages are 
known to participate in efferocytosis within the alveolar space, the dynamics between the cells 
involved in host defense in the lung tissue/interstitium are not well defined and no cell has yet 
been found to participate in clearance of apoptotic neutrophils in the intersititum.  This is a 
critical question given that “interstitial neutrophils are more intimately associated with clinically 
relevant measures of acute lung injury” (Fessler, 2005 #380).   
IL-10 has been shown to impair neutrophil recruitment thereby dampening host 
defense166.  This suggests that high IL-10 concentration during the initiation phase is detrimental 
to the host because neutrophil recruitment is impaired via suppression of relevant 
 98 
chemokines165,166.  However, IL-10 is also known to be important for maintenance of 
homeostasis as well as regulation of neutrophil clearance, specifically promoting phagocytosis of 
apoptotic neutrophils (efferocytosis)126.  The role of IL-10 as both a negative regulator of 
bacterial clearance but a positive regulator of homeostasis pointed to a seemingly contradictory 
need for a source of IL-10 which is absent during initial host defense but present following 
infection.  Until now, a cellular source of IL-10, which aids in homeostatic resolution in the lung 
interstitium, had not been identified.  Furthermore, the requirement for late IL-10 production 
following infection had not been rigorously tested.  Our studies reveal the role of lung MDSCs as 
tissue dwelling cells with efferocytic and IL-10 producing capability.  They expand over the 
course of 72 hours to exert a regulatory force via IL-10 production after initial host defense and 
adequate neutrophil recruitment has occurred.   
Finally, we wanted to better understand the mechanism(s) the host may use to control 
MDSC expansion at earlier time points but allow for proliferation when resolution is necessary.  
Since we demonstrated that lung MDSC participate in clearance of apoptotic neutrophils, more 
detailed understanding of the mechanisms that control their development would theoretically 
result in novel clues towards potential future therapeutic development.  To address this issue we 
explored a number of possibilities including signaling through both the GM-CSF-STAT5A, and 
IL-6 pathways in an attempt to better understand MDSC development in the lung tissue.  
Furthermore, we investigated the role of STAT1 in lung MDSC development and function given 
the role of STAT1 as a STAT3 antagonist and the published centrality of STAT3 signaling in 
tumor MDSC development and function1.  STAT1/STAT3 antagonism has been discussed 
extensively in the literature.  For example, IFNγ is able to signal via STAT3 in the absence of 
STAT1 suggesting some redundancy in their role but also the opportunity for counter-regulatory 
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control90. We now show that ablation of STAT1 results in increased frequency of lung MDSCs 
as well as increased production of IL-10.  We propose the use of STAT1 inhibition in 
combination with systemic antibiotic administration as a potential novel therapy for the treatment 
of non-resolving pneumonia. 
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5.0  FUTURE DIRECTIONS 
The current work has contributed to the field of MDSC biology and the understanding of 
regulation of inflammation in the lung following bacterial pneumonia.  However, many questions 
remain unanswered and many of these are extremely relevant for the development of potential 
future therapies. 
This discovery of MDSC accumulation in the lung, presumably resulting from trafficking 
of progenitor cells into the tissue, highlights a way the immune system has evolved to minimize 
global immunosuppression.  In the case of immunosuppression in the lung after bacterial 
clearance, it is necessary for the MDSCs to remain compartmentalized, lest their 
immunosuppressive effects result in sepsis.  Futher work as to the origin and accumulation of 
lung MDSCs is of great interest and relevant for harnessing their therapeutic potential.  To this 
end, we have already initiated studies regarding the role of CX3CR1 vs CCR2 in the 
accumulation of lung MDSCs. 
 We have also observed that MDSC IL-10 production seems to be inhibited during 
overwhelming infection, suggesting that although the immune system may dampen IL-10 in the 
hopes of augmenting host defense and facilitating neutrophil influx, this dampening of IL-10 
could inevitably result in increased mortality due to destructive lung inflammation.  
Identification of the soluble factors and signaling molecules related to the decrease in IL-10 
production is an area of interest for our laboratory.  As one example, STAT3 has two isoforms 
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STAT3α and STAT3β.  STAT3α has recently been linked to an IL-6 response and production of 
IL-10 in macrophages indicating that further investigation into IL-10 production by lung MDSCs 
is warranted225. 
Another area of interest revolves around the role of MDSCs in actual bacterial clearance.  
We observed lung MDSCs to be highly phagocytic both in vitro even to the extent of having 
phagocytosed K. pneumoniae in vivo (Figure 31).  Although MDSCs were able to also 
phagocytose E. coli in vitro, the observation of K. pneumoniae inside isolated MDSCs ex vivo 
may not be necessarily due to direct phagocytosis.  We have not attempted to address whether 
the K. pneumoniae is directly phagocytosed by MDSCs, or if what we observed is simply the 
result of MDSCs efferocytosing neutrophils that have previously phagocytosed K. pneumoniae in 
vivo.  The possibility exists that it may be a combination of the two, but the engulfment of 
bacteria-containing neutrophils may be one way that host defense is perpetuated towards 
resolution of inflammation.  Referred to as nonphlogistic clearance of bacteria, MDSCs may be a 
major player in the lung due to the simultaneous engagement of apoptotic surface molecules on 
PMNs.  Blander and colleagues have elegantly discussed this concept in their work regarding 
promotion of IL-17 responses downstream of simultaneous engagement of TLRs in the presence 
of apoptotic cells226,227.  Indeed, the regulation of a Th17 response by lung MDSCs is an area of 
future interest for our laboratory. 
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Figure 31. Gr1int cells can phagocytose Gram-negative bacteria in vitro and in vivo. 
(a) CD11b cells were purified from the lungs following LPS treatment by magnetic separation and incubated with 
pHrodo dye-conjugated E.coli (invitrogen). Using flow cytometry Gr1int and Gr1hi cells were distinguished and 
examined for labeled E.coli. Incubation at 4°C was used as a negative control for physiological internalization of 
bacteria.   (b) Gr1int cells isolated from K. pneumoniae infected mice contain K. pneumoniae with increased 
frequency in 1000 CFU infected animals as compared to 100 CFU infection, 72 hours post infection.  Cytospins of 
purified Gr1int cells were immunostained for K. pneumoniae and counterstained with hematoxylin.  Percent positive 
for K. pneumoniae was determined.   
 
Speculation regarding the role of lung MDSCs in nonphlogistic clearance of bacteria 
would also involve future studies determining which receptors are involved in MDSC 
recognition and efferocytosis of apoptotic neutrophils in the lung.  Although we investigated the 
transcription levels of many receptors via qPCR, none stood out as being differentially 
expressed, suggesting that regulation of function and downstream signaling may be more 
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relevant than simple expression levels.  If relevant cellular receptors were to be identified, then 
their associated signaling pathways would represent ideal targets for modulation, with the goal of 
enhancing neutrophil clearance in vivo.  
Finally, and most relevant for therapeutic development in the context of the current state 
of knowledge, is the potential for inhibition of STAT1 as a therapy for non-resolving pneumonia.  
We feel that simultaneous administration of systemic antibiotics with local delivery of a STAT1 
inhibitor around 48 hours post infection will yield the best result towards the timely resolution of 
inflammation in the lung.  We are currently conducting these studies in the laboratory. 
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